








Omslag Rifka Peeters def.pdf   11-10-2007   22:19:23
Don’t be afraid!
Population PK-PD modeling as the basis for individualized 
dosing in children and critically ill

Don’t be afraid!
Population PK-PD modeling as the basis for individualized 
dosing in children and critically ill
Proefschrift
ter verkrijging van 
de graad van Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof.mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties
te verdedigen op woensdag 28 november 2007
klokke 15.00 uur
door




Promotoren:  Prof. Dr. M. Danhof
  Prof. Dr. D. Tibboel
Co-promotor: Dr. C.A.J. Knibbe
Referent: Prof. Dr. A. Dahan
Overige leden: Prof. Dr. L.P.H.J. Aarts
  Prof. Dr. J.A. Bouwstra
  Prof. Dr. A.F. Cohen
  Prof. Dr. J. van der Greef
  Prof. Dr. H.J. Guchelaar

The investigations described in this thesis were performed at the Department of Clinical 
Pharmacy and the Department of Anaesthesiology and Intensive Care of the St Antonius 
Hospital in Nieuwegein, the Division of Pharmacology of the Leiden/Amsterdam Center 
for Drug Research, University of Leiden and the Department of Pediatric Surgery, Erasmus 
Medical Center-Sophia Children’s Hospital, Rotterdam, The Netherlands.
ISBN: 978-90-6464-192-3
No part of this thesis may be reproduced, stored in a retrieval system, or transmitted in any 
form or by any means without permission of the author, or when appropriate, the publisher 
of the manuscript.
Layout, cover design and photographs:
Paula Berkemeyer, Amersfoort, www.PBVerbeelding.nl
Printed by: Ponsen & Looijen BV, Wageningen
Contents
Introduction
Chapter 1 Population PK-PD modeling as the basis for individualized dosing 
in children and critically ill
11
Sedation in pediatrics 
Chapter 2 Propofol 6% as a sedative in children under 2 years of age following 
major craniofacial surgery
25
Chapter 3 Propofol pharmacokinetics and pharmacodynamics for depth of 
sedation in nonventilated infants after major craniofacial surgery
37
Chapter 4 Pharmacokinetics and pharmacodynamics of midazolam and me-
tabolites in nonventilated infants after craniofacial surgery
57
Sedation in critically ill patients
Chapter 5 Comparative evaluation of sedation guidelines and clinical practice 
in long-term sedated critically ill patients
81
Chapter 6 Disease severity is a major determinant for the pharmacodynamics 
of propofol in critically ill patients
93
Chapter 7 Pilot study on the influence of liver blood flow and cardiac output
on the clearance of propofol in critically ill patients
111
Discussion and perspectives
Chapter 8 Population PK-PD modeling of propofol and midazolam in children 
and critically ill: discussion and perspectives
125
Samenvatting (Synopsis in Dutch) 139
Nawoord (Epilogue in Dutch) 145





Population PK-PD modeling as the 
basis for individualized dosing 
in children and critically ill

13
Introduction on sedation in pediatrics and long-term intensive care 
Anxiety, agitation, delirium and pain are common in the adult and pediatric intensive care 
unit ((P)ICU). These “unhealthy” states may lead to increased discomfort, motor activity, 
self-extubation and psychological derangements leading to hypertension, tachycardia, 
and even cardiac ischemia. The appropriate treatment of these conditions may lead to a 
decreased morbidity and mortality in critically ill patients.1-3 In the past decade, the level 
of sedation thought to be optimal has changed from deeply sedated and even paralyzed 
to light sedation.4 Improvements in ventilator technology have been associated in this 
respect. In the meantime there is strong evidence that patients who are over sedated may 
be exposed to excessive mechanical ventilation, leading to associated complications such 
as ventilator-associated pneumonia,5 delirium,6 and post-ICU psychological effects.7 Daily 
interruptions of sedation and the use of a sedation protocol have been shown to reduce the 
length of mechanical ventilation and the length of stay in the ICU.8-10 In infants and children 
the increased use of sedatives in the first 24 h of weaning from mechanical ventilation has
been associated with failure of extubation.11 As a result of these and other observations, 
consensus recommendations to guide analgesic and sedative therapy were provided for both 
the adult and the pediatric intensive care unit (ICU).12,13
Recommended choices of sedatives in the adult intensive care are: for rapid sedation: 
midazolam or diazepam; for short-term sedation (≤ 24 h): midazolam; for long-term sedation: 
lorazepam; and when rapid awakening is crucial: propofol.12 In pediatrics, midazolam is the 
recommended and most commonly used sedative.13
Midazolam is a short acting benzodiazepine.14 Disadvantages are the formation of active 
metabolites by the cytochrome P450 isoenzyme 3A4 which can accumulate, particularly in 
renal failure,15 the possibility of the development of paradoxical reactions in children and 
elderly, and its longer and more variable recovery time after stopping compared to propofol. 
Moreover, with long-term infusion, drug-drug interactions may become important. Finally, 
in preterm neonates an increased incidence of poor neurological outcome (as intraventri-
cular hemorrhage) has been reported.16
Lorazepam is a benzodiazepine, of which the pharmacokinetics is relatively independent 
of liver function or co-medication with other drugs.17 Due to its longer terminal half-life 
compared to midazolam,18 questions have been arisen about its value for long-term use.19
Propofol (2,6-diisopropyl phenol) allows a quick recovery in patients receiving either short-
term or long-term sedation, as well as an easily controllable level of sedation, because of its 
unique pharmacokinetic profile.20 Known adverse effects of propofol administration include 
cardiovascular depression, transient oxygen desaturation and in case of long sedation times 
(> 72h) a progressive rise in triglycerides, probably due to the fat vehicle.21 This fact has 
motivated the development of a more concentrated formulation (60 mg/L; propofol 6%), 
which reduces fat load three to six times compared to the commercially available Diprivan-
10 (Propofol 1%) and Diprivan-20 (Propofol 2%), while maintaining the same pharmacoki-
netic and pharmacodynamic properties.22-27 Propofol has also gained great popularity in the 
pediatric population, but its routine use is not recommended for prolonged use in the intensive 
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care unit and even contraindicated, because of the association with the “propofol infusion 
syndrome,” which manifests itself as dysrhythmias, heart failure, metabolic acidosis, hyper-
kalemia, and rhabdomyolysis.28-30 To date, use of propofol in the ICU in neonates have been 
reported for short procedural sedation.31
Although consensus recommendations have been established for sedation, the management 
of sedation in the ICU is not ideal in practice.32-34 As a result optimization of sedation is 
still a matter of debate.17,32,35 One of the reasons is that no single dose is appropriate for the 
critically ill (pediatric) patient, while trial and error may lead to oversedation and adverse 
events.
Thus, optimal sedation of patients in the ICU requires individualized dosing. The investiga-
tions in this thesis focus on the use of population PK-PD modeling as the basis for individu-
alized dosing of sedatives in pediatrics and critically ill.
Mechanisms of intra- and interindividual variability in response
Patients’ responses to sedatives are often unpredictable, because of large inter-individu-
al differences in the pharmacokinetics and the concentration-effect relationships between 
patients.23,36-41 Especially in critically ill patients who usually present with changing hemo-
dynamic instability and failure of one of more organs, large differences in infusion rates are 
required to achieve the same degree of sedation. For example the infusion rate of midazolam 
required has been shown to vary among patients by a factor of five.42 In pediatric intensive 
care patients (aged 2 days to 17 years) no clear pharmacokinetic – pharmacodynamic rela-
tionship was found.37 During childhood, many physiological changes take place, which may 
have an impact on the PK and PD of a certain sedative.
According to the literature, the optimal dose of midazolam may vary as a result of many 
factors, including hepatic blood flow which may be affected by mechanical ventilation,
hepatic and renal function, the condition of patients and the enzyme activity of the cyto-
chrome P450 3A subfamily during the first year of age.18,40,43,44
For propofol, covariates as weight, age, gender, cardiac output and albumin have been 
shown to influence the pharmacokinetics,23,45-49 whereas an increased sensitivity to propofol 
has been shown in elderly patients.50 In children, larger doses are required and it has been 
suggested that this is due to differences in pharmacokinetics and/or sensitivity.51,52 
However, large (observed) inter-individual variability in the effect of sedatives remain un-
explained so far, which complicates dosing in clinical practice and may indeed increase the 
risk of over sedation and adverse events.
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Research on intra- and interindividual variability in response to 
sedative drugs
As a response to the clinical need for safe and correct dose administration, dosing schemes 
should be developed with accurate endpoints.
Several observational sedation scoring systems have been developed and tested in a variety 
of clinical settings.53 The Ramsay score,54 a six point scale, is the most widely used scale 
for monitoring sedation in adult ICU patients as well as in clinical research. The Ramsay 
score has a demonstrated good inter-rating reliability,55 but it has been criticized by the fact 
that it is based on a motor response. In children, the COMFORT scale56  is recommended,13 
which scores the variables – mean arterial blood pressure, heart rate, muscle tone, facial 
tension, alertness, calmness/agitation, respiratory behavior and physical movement –after 
a 2-min period of observation. The COMFORT-behavior (COMFORT-B) scale,57,58 is a 
reliable alternative and is routinely used in most PICUs in the Netherlands. The Bispectral 
Index (BIS) is based in part on a bispectral analysis of the electroencephalogram. In the 
bispectral analysis, the weight factors of the various subparameters were assigned in a mul-
tivariate model based on a prospectively collected database of EEG recordings from adults 
and matched to the corresponding states of hypnosis. The BIS algorithm uses a complex 
formula with advanced techniques to define a dimensionless BIS value from 0 (complete
cortical EEG suppression) to100 (fully awake).59 The Bispectral index has been developed 
as a tool to measure the level of consciousness during anesthesia and has theoretical benefits
in comparison to clinical measures of sedation, because it assesses sedation continuously 
and may provide an objective, quantitative measure of the level of sedation. The Bispectral 
index has been approved for use in the operating room. However, it is also used to evaluate 
depth of sedation in the ICU patients. BIS values have shown a marginal to good correla-
tion with sedation scores in children and adults.60-62 In pediatric patients older than 1 year 
of age, the technology appears to perform in a similar manner to the adult population. In 
younger infants, brain maturation and development may render processed EEG measures 
unreliable. Technical limitations have been reported for the critical care environment such as 
EMG interference63 and influence of environmental factors.64 As a result, at present the BIS 
requires more validation before its role is established in the (P)ICU.12,13,62
An important tool for development of dosing guidelines is pharmacokinetic and pharma-
codynamic modeling. In particular, Nonlinear Mixed Effect Modeling (NONMEM) is an 
interesting approach for clinical practice, as it describes and explores factors (covariates) 
influencing intra- and inter-patient variability, in contrast to traditional study designs in
which variability is typically minimized by restricting inclusion criteria.65 The approach 
analyses data from all individuals simultaneously which may be sparse and unbalanced. 
As frequent sampling is not necessary, the method is also of special interest for application 
in children and in particular in neonates due restrictions in the maximum number of blood 
samples that may be obtained. The population model comprises three sub-models: 1) struc-
tural, 2) statistical and 3) covariate model. The structural (PK or PD) sub-model describes 
the overall trend in the data. For the PK, this can be a two-compartment model and for the 
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PD (e.g. the level of sedation, this may be a sigmoid Emax model for continuous data such 
as the COMFORT-B and BIS or a proportional odds model for categorical data such as the 
Ramsay sedation scale. The statistical sub-model accounts for variability by using two levels 
of random effects: inter-individual variability and intra- or residual variability. The covariate 
sub-model expresses relationships between covariates and PK or PD model parameters, 
using fixed effects parameters. Covariate analysis involves the modeling of the distribution
of the individual parameter estimates as a function of patient characteristics (e.g. age, body 
weight, gender), pathophysiological factors (e.g. renal or hepatic function), genetic/environ-
mental factors and/or the concomitant use of other drugs, which may influence the PK and/or
PD. The identification of predictive covariates for variability provides the scientific basis
for rational and individualized dosing schemes. In NONMEM parameters are estimated via 
a maximum likelihood approach, whereby the joint function (the objective function) of all 
model parameters and the data (the observations) is evaluated. The maximum likelihood 
parameter estimates are the parameter estimates yielding the greatest probability that the 
given data occur. Goodness of fits plots including observations vs. individual predictions, 
observations vs. population predictions, weighted residuals vs. time and population predic-
tions vs. weighted residuals are used for diagnostic purposes of both pharmacokinetic and 
continuous pharmacodynamic data. For categorical pharmacodynamic data “naïve pooled 
observed” probabilities are defined. Furthermore, the confidence interval of the parameter
estimates, the correlation matrix and the visual improvement of the individual plots are used 
for evaluation. For the identification of covariates, scatter plots of covariates vs. individual 
post-hoc estimates and the weighted residuals are valuable for visualization of potential rela-
tionships followed by stepwise testing for statistical significance. For testing the developed
model, external validation provides the most stringent method. When a test data set is not 
available and the sample size is small (especially in pediatric studies), the bootstrap approach 
can be useful, in which the mean parameter values obtained by repeatedly fitting the final
model to the bootstrap replicates are compared to the final parameter estimates from the
original data set.
In the meantime, population PK-PD modeling has been successfully implemented in many 
clinical studies, mostly initiated by the industry and it is encouraged for use in clinical 
investigations in children nowadays. In children, only 25-50% of drugs used are licensed 
for this population.66,67 As a result, the common approach for dosing of unlicensed or off-
label drugs in children is to use clinical data from adults and to adjust the dose according to 
the child’s weight.68 It has been amply demonstrated that this may result in adverse events 
because the differences in pharmacokinetics and pharmacodynamics in different age groups, 
governed by differences in (organ) function which may change independent of body weight. 
The European Medicines Agency and the Pediatric Working Party (EMEA/496777/06) 
have recently released a priority list of off-patent medicinal products for pediatric studies 
to increase the availability of licensed drugs. Unfortunately, NONMEM is not often applied 
in clinical (pediatric) practice. Most clinicians view this approach and the models as com-
plicated, requiring technically sophisticated knowledge without proven clinical utility. We 
believe that in particular interaction between clinicians and experts in PK-PD modeling may 
result in rational dosing guidelines for drugs currently used in clinical practice.
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Objective of the thesis
The overall goal was to develop novel strategies to individualize sedative dosing in the 
special group of infants and critically ill patients, on the basis of population pharmacoki-
netic-pharmacodynamic (PK-PD) modeling. In the investigations the emphasis was on the 
modeling of the influence of the covariates age, severity of illness and organ failure on the
pharmacokinetics and pharmacodynamics of the sedatives propofol and midazolam.
Outline of the thesis:
Sedation in pediatrics
Propofol and midazolam were studied in a population of relatively healthy non-ventilated 
infants aged 3-24 months following craniofacial surgery. Chapter 2 describes the clinical 
results obtained with propofol in this patient group and focuses specifically on the evalua-
tion of the safety as the use of propofol is still controversial in the pediatric intensive care. 
No adverse events in terms of increased triglycerides, creatine phosphokinase or metabolic 
acidosis were observed, using dosages < 4 mg · kg-1 · h-1, during a median of 11 h. In Chapter 
3 dosing guidelines are developed for propofol, based on population pharmacokinetic and 
pharmacodynamic modeling, using the COMFORT-B score and the BIS as pharmacody-
namic endpoints. A remarkably high clearance of propofol was found, which was shown 
to be influenced by bodyweight. Moreover, a very high interindividual variability in the
pharmacodynamics (i.e. the brain sensitivity to propofol) was described. The investigations 
in Chapter 4 focus on the pharmacokinetic-pharmacodynamic modeling of midazolam. As 
found for propofol, the clearance of midazolam was relatively high. The interindividual 
variability in pharmacodynamics on the COMFORT-B was 89%, thereby showing a less 
predictable effect than propofol (47%).
Sedation in critically ill patients
Propofol was studied in the population of critically ill patients, who are characterized by high 
variability in dosing requirements between and within patients. In Chapter 5 we evaluated 
the implementation of a sedation protocol in the ICU. The findings of our study show, that
in practice, on average patients were deeper sedated by the nurses than was intended by the 
physicians. In Chapter 6 the influence of the severity of illness (expressed as Sequential
Organ Failure Assessment; SOFA score) of the patients was studied on the pharmacokinetics 
and pharmacodynamics, using the Ramsay and BIS as pharmacodynamic endpoints. It was 
shown that severity of illness is a major determinant of the response to propofol, with the 
patients with the highest SOFA score requiring the lowest doses for adequate sedation. In 
Chapter 7 the influence of variability in liver blood flow (as determined on the basis of the
sorbitol clearance) and cardiac output on the pharmacokinetics of propofol were explored in 
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a preliminary study. It was shown that the variability in hepatic blood explains a large part of 
the variability in propofol clearance. It was also shown that in this patient group variability 
in hepatic blood flow is unrelated to variability in cardiac output.
Discussion and perspectives
The results of the investigations described in this thesis are reviewed and discussed in 
Chapter 8. In addition, prospective use of developed population models were tested for 
their predicted value in the youngest pediatric age group, namely neonates, using allometric 
scaling (between species and within children) and the per kg model.
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Abstract
Background: After alarming reports concerning deaths after sedation with propofol, infusion 
of this drug was contraindicated by the US Food and Drug Administration in children <18 
yr receiving intensive care. We describe our experiences with propofol 6%, a new formula, 
during postoperative sedation in nonventilated children following craniofacial surgery.
Methods: In a prospective cohort study, children admitted to the pediatric surgical intensive 
care unit following major craniofacial surgery were randomly allocated to sedation with 
propofol 6% or midazolam, if judged necessary on the basis of a COMFORT-Behavior score. 
Exclusion criteria were respiratory infection, allergy for proteins, propofol or midazolam, 
hypertriglyceridemia, familial hypercholesterolemia or epilepsy. We assessed the safety of 
propofol 6% with triglycerides (TG) and creatine phosphokinase (CPK) levels, blood gases 
and physiological parameters. Efficacy was assessed using the COMFORT-Behavior scale,
Visual Analogue Scale and Bispectral index™ monitor.
Results: Twenty-two children were treated with propofol 6%, 23 were treated with midazolam 
and 10 other children did not need sedation. The median age was 10 (IQR 3-17) months in all 
groups. Median duration of infusion was 11 (range 6-18) h for propofol 6% and 14 (range 5-17) 
h for midazolam. TG levels remained normal and no metabolic acidosis or adverse events were 
observed during propofol or midazolam infusion. Four patients had increased CPK levels.
Conclusion: We did not encounter any problems using propofol 6% as a sedative in children 
with a median age of 10 (IQR 3-17) months, with dosages < 4 mg kg
-1 h-1, during a median 
period of 11 (range 6-18) h.
Introduction
Propofol for sedation in children has become controversial after reports describing the propofol 
infusion syndrome, which is characterized by increased triglyceride (TG) levels,1,2 myocar-
dial failure,1-3 rhabdomyolysis,2,3 metabolic acidosis,1-3 hyperthermia1 and death.1 Therefore a 
warning was issued against use of propofol as a sedative in children < 18 years in intensive 
care.4
In Diprivan®-10, propofol is formulated in Intralipid® 10 %. Long-term infusions of Diprivan®-10 
have been associated with increases in serum lipid levels, notably TG.3 In order to reduce the 
volume and amount of lipids, a new formulation of propofol 6% in Lipofundin® MCT/LCT 
10% (propofol 6%) was developed and tested in animals,5 adults6 and six children.7
In contrast with propofol, midazolam is a widely used sedative for children.8,9 On initial admin-
istration, it has a short duration of action.10 However, paradoxical reactions such as agitation,11 
convulsions, hyperactivity or adverse reactions12 have been reported in neonates and children.13 
Also, the active metabolites and prolonged effect of midazolam often delay awakening and 
weaning from mechanical ventilation.14,15 A new formula for propofol would be an alternative 
or additional sedative in children receiving intensive care. In view of the existing controver-
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sies, we present our experiences with propofol 6% as a postoperative sedative in nonventilated 
children < 2 yr of age following major craniofacial surgery.
Materials and Methods
With approval from the Erasmus MC research ethics board and written consent from a parent 
or legal guardian, from July 2002 until September 2003 we studied children aged between 1 
month and 2 yr of age admitted to our pediatric surgical intensive care unit (PSICU) during 
the first 24 h after elective craniofacial surgery. Exclusion criteria for propofol were known
allergies for proteins, egg or propofol, respiratory infections, hypertriglyceridemia, epilepsy, 
familial hypercholesterolemia or weight < 6 kg.
At least 1 day before surgery, the parents of eligible patients were asked to give written informed 
consent for either propofol or midazolam. If consent for propofol was refused, consent was 
asked for midazolam, even though midazolam is our standard of care. Four patients were 
excluded from receiving propofol on the ground of familial hypercholesterolemia, one patient 
was excluded as his TG level was 2.62 mmol litre-1 the day before surgery, probably because 
he had been fed just before blood sampling, and parents of two patients refused consent for 
propofol. These seven patients received midazolam for sedation instead of propofol.
Perioperative procedure
Anesthesia was induced with either sevoflurane or i.v. thiopental. An arterial line and a central
venous line were placed for clinical purposes and blood was drawn to evaluate liver and 
kidney function, TG level and creatine phosphokinase (CPK) level. After i.v. administration of 
vecuronium 0.1 mg kg-1 and fentanyl 2.5 μg kg-1, the trachea was intubated and ventilated with 
air, oxygen and isoflurane. Approximately 2 h before anticipated extubation, acetaminophen
40 mg kg-1 was administered rectally as previously described.16 After surgery, the trachea was 
extubated and the patient was transferred to the PSICU, where heart rate, arterial pressure, 
oxygen saturation and central venous pressure were monitored continuously. Body tempera-
ture was measured every 2 h. Routine postoperative care included evaluation of haemoglobin, 
haematocrit, thrombocytes, white blood count and arterial blood gases. The children received 
no parenteral nutrition during the study period.
Sedation and analgesia protocol
On admission to the PSICU, usually in the early afternoon, sedation and analgesia levels 
were assessed using the COMFORT-Behavior scale and the Visual Analogue Scale (VAS). 
At COMFORT-Behavior scores < 17, no sedatives were given. At scores ≥ 17, propofol or 
midazolam was started. At VAS scores ≥ 4, more analgesia was given. During the first 2 h after
start of sedation, sedation and analgesia levels were assessed at least three times using the 
COMFORT, VAS and Bispectral Index (BIS) values. After the first 2 h, the level of sedation
was assessed every 2 h until the next morning. If the COMFORT-Behavior score remained ≥ 
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17 after administration of a sedative, propofol and midazolam dosing were increased by 0.1 
ml h-1 and 0.025 mg kg-1h-1, respectively. If scores remained ≥ 17 during propofol infusion of 
a maximum of 4 mg kg-1h-1, midazolam was added. At scores < 9, propofol and midazolam 
dosing were decreased by 0.1 ml h-1 and 0.025 mg kg-1h-1, respectively.
At 8 a.m. the next morning, the sedatives were stopped to allow the patients to wake up and 
prepare for transfer to medium care. The effects of stopping the infusion were assessed using 
the COMFORT, VAS and BIS for the next 2 h. At approximately 11 a.m., all children were 
transferred to medium care.
The COMFORT-Behavior scale
The COMFORT-Behavior scale is an adapted version of the scale that was originally developed 
by Ambuel et al.17 in 1992 and consists of six behavioural items and two physiological param-
eters, heart rate and blood pressure. Marx et al.18 showed that this scale was useful to assess 
sedation. We showed that, leaving out the physiological items, the scale was still valid for 
both postoperative pain and sedation in children aged 0-3 yr.19 The COMFORT-Behavior scale 
assesses six patterns of behaviour: alertness, calmness, muscle tone, body movement, facial 
tension, crying (nonventilated children) or respiratory response (ventilated children). The total 
score ranges from 6 to 30: the higher the score, the more uncomfortable the child is. All nurses 
were trained to use the COMFORT-Behavior scale, as reported in our earlier analgesia study. 
Inter-observer reliability, represented by linearly weighted κ was satisfactory, with κ > 0.65 
for all nurses and principal investigator. A COMFORT-Behavior score < 9 represents over-
sedation, score between 9 and 17 represents no distress and ≥ 17 represents distress.
Bispectral index monitor
Sedation was assessed continuously using a Bispectral A 2000 version 3.12 monitor (Aspect 
Medical Systems, Natick, MA, USA) with commercially available pediatric BIS sensors 
applied according to the manufacturer’s instruction manual. We used the impedance limits set 
in the monitor: if the signal quality index was > 50, the BIS value was recorded.
Visual Analogue Scale
To determine whether restlessness might be induced by pain, analgesia levels were assessed 
using the VAS. At VAS scores ≥ 4, more analgesia was given. If the VAS score was < 4 and the 
COMFORT-Behavior ≥ 17, a sedative was given.
Determining safety
Before, during and 2 h after stopping the infusion of propofol or midazolam, we determined 
TG and CPK levels to evaluate the influence of propofol on these variables. We used an
enzymatic and colorimetric in vitro test, with a Hitachi analyser (Roche Diagnostics, GmbH, 
Mannheim, Germany). TG levels in the range 0-1.6 mmol litre-1 and CPK levels < 230 U litre-1 
were considered normal.20 We defined desaturation as saturation < 95% for > 5 s and requiring
intervention. Hypotension was defined as any period of time when a patient’s arterial pressure
was 10-15% below the arterial pressure mentioned in Table 1. Bradycardia was defined as any
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period of time when a patient’s heart rate was <80 beats min-1 (see Table 1). Hyperthermia was 
defined as body temperature > 38.3ºC. Metabolic acidosis was defined as arterial pH < 7.30
with a concomitant PaCO2 < 4.7 kPa. All physiological parameters, except temperature, were 
screened hourly using a computer-guided patient data management system.
Determining efficacy
To compare efficacy of propofol with that of midazolam, we considered COMFORT-Behavior,
VAS scores and BIS values in four groups: children receiving propofol, children receiving 
propofol with additional midazolam, children receiving midazolam and children who did not 
need sedation. Additionally, we determined the dose change frequency, i.e. the number of 
times that dosing of propofol or midazolam was adjusted.
Medication preparation
Propofol 6% was prepared in the Department of Clinical Pharmacy, St. Antonius Hospital, 
Nieuwegein, The Netherlands.21 Propofol 6% was given through the central venous line in 
order to prevent pain from injection. Midazolam hydrochloride was dissolved in glucose 5% 
to make an i.v. solution.
Statistical analysis
The data were analysed using SPSS for Windows (version 10,0; SPSS, Chicago, IL). The 
safety parameters of children receiving propofol 6% and those receiving no propofol 6% were 
compared using the Mann-Whitney U-test. Statistical differences were considered signifi-
cant if P < 0.05. A correlation r of 0.10-0.29 was considered small, 0.30-0.49 was considered 











Patients, M/F 11 / 6 4 / 1 17 / 6 5 / 5
Age, months 9 (4-17) 12 (11-17) 11 (3-15) 9 (4-13)
Weight, kg 9 (6-13) 10 (9-10) 10 (5-12) 8 (6-10)
Duration of surgery, h 5 (4-7) 4 (4-5) 5 (3-7) 5 (3-6)
Duration of infusion of 
sedatives, h
12 (6-17) 10 (7-18) 13 (4-17) *N/a




Baseline arterial pressure, 
mm Hg
55 (35-100) 50 (40-60) 51 (35-82) 52 (45-55)
Baseline heart rate,
beats min-1
129 (90-180) 127 (95-150) 113 (80-153) 121 (105-140)
Table 1 Patient characteristics. Data are median (range). *N/a, not applicable
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Results
We studied 55 patients, with a median age of 10 (IQR 3-17) months and weight 9 (5-13) kg. Pre-
operative diagnoses were scaphocephaly (n=26), trigonocephaly (n=18), brachycephaly (n=2), 
encephalocele (n=1), plagiocephaly (n=5) and Saethre-Chotzen syndrome (n=3). There was no 
significant differences between the groups with regard to age, weight, duration of surgery or
duration of infusion of sedatives (Table 1).
In one patient the TG level was 2.00 mmol litre-1 during propofol infusion without metabolic 
acidosis, disturbance in physiological parameters or increase of CPK levels (Figure 1). Four 
patients had raised CPK levels, ranging from 261 to 313 U litre-1 during and after the end of 
infusion (Figure 2). Three patients had received propofol and one patient had no medication. 
Two patients receiving propofol had elevated CPK levels before the start of infusion and one 
of these patients had elevated CPK levels during and after infusion. The first patient had CPK
levels of 261 U litre-1 before infusion. The second patient had CPK levels of 336 U litre-1 
before infusion, 276 U litre-1 during infusion and 240-282 U litre-1 after infusion. One patient 
receiving propofol had a CPK level of 313 U litre-1 after infusion. These patients showed no 
acidosis, no abnormal physiological parameters and no increased TG levels.
There were no respiratory complications. Three patients, one receiving propofol and two 
receiving midazolam, experienced short periods of desaturation with spontaneous recovery.
Median minimal arterial pressure was 56 mm Hg and 59 mm Hg for propofol 6% and no 
propofol 6%, respectively (Mann-Whitney U-test, 330; P=0.57). Median minimal heart rate 
was 110 beats min-1 and 111 beats min-1 for propofol 6% and no propofol 6%, respectively 
(Mann-Whitney U-test, 353; P=0.86). One episode of bradycardia lasting 90 s (median of 77 
beats min-1) was observed in a patient receiving midazolam. The median maximal tempera-































Figure 1 Triglyceride levels
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A total of 915 paired COMFORT-Behavior scores, VAS and BIS values were obtained with 
a median of 15 (IQR 13-18) observations per patient. During infusion of propofol 6% median 
COMFORT and BIS values were 11 (9-18) and 78 (65-91), respectively. During infusion of 
midazolam, median COMFORT and BIS values were 11 (9-15) and 77 (63-91), respectively. 
VAS was ≥ 4 in only seven observations in seven children (less than 1% of all observations). 
The starting dose of propofol was sufficient in three children (< 14 %). A propofol infusion of
4 mg kg-1 h-1 was not sufficient in five cases (~ 23% of the propofol group), and these patients
received additional sedation with either a single dose of midazolam (two patients), multiple 
doses (two patients) or continuous midazolam infusion (one patient) (median rate 0.05 mg 
kg-1h-1).
One of the patients receiving midazolam became agitated and more restless after administra-
tion of up to 0.2-mg kg-1h-1 maintenance infusion and five doses of midazolam.
Discussion
We did not encounter any problems with propofol 6% in dosages < 4 mg kg-1h-1 in children 
with a median age of 10 (IQR 3-17) months during a median period of 11 (range 6-18) h.
Propofol doses of 2 mg kg-1h-1 were insufficient to maintain an adequate sedation level in >
86% of the children. Midazolam was insufficient in only 21% of the children. The TG level was
2.0 mmol litre-1 in only one patient, during propofol infusion, without abnormalities in other 
physiological parameters. This patient had been fed with formula milk Nutrilon 1 (Nutricia, 
Zoetermeer, The Netherlands), just before blood sampling. Four other patients had increased 
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CPK levels, without other signs of the propofol infusion syndrome.22,23 An increase of the CPK 
level can also be a valid indication of the extent of muscle damage. Muscle damage due to 
major muscle-cutting surgery, such as craniofacial surgery, has been reported and should be 
taken into account when interpreting CPK levels postoperatively.23 CPK levels 10 times higher 
than normal are regarded as a warning sign for rhabdomyolysis.23
A review of the literature yields reports both for and against the use of propofol as a sedative 
in children. Seventeen publications support propofol use in children at the pediatric intensive 
care unit (PICU). Pepperman and Macrae24 found no differences in mortality between propofol 
and other sedative agents in 198 children. Cornfield et al.25 described continuous infusion of 
propofol in 142 critically ill children, with a mean age of 5 yr 9 months. Ten showed metabolic 
acidosis and 10 died during the first week of propofol infusion. These deaths could all be at-
tributed to the primary diagnosis. Martin et al.20 described nine children on mechanical ven-
tilation receiving propofol for sedation and concluded that it was useful and safe. Knibbe et 
al.7 evaluated propofol for sedation for < 6 h sedation in six children aged 1-5 yr, following 
cardiac surgery, and found no adverse events. A number of authors have published guides to 
drug selection and use in the PICU.8,14,26,27 They acknowledge that propofol infusion may cause 
problems and therefore suggest avoiding it in patients with sepsis, respiratory infections or 
underlying metabolic problems,8 avoiding infusion for > 24 h8,14 and taking into account the 
lipid content of propofol when calculating patients’ daily caloric intakes.14,26
Fourteen publications and one unpublished trial outline adverse events and deaths associated 
with propofol. Twelve publications pertain to children, four of which are case reports describ-
ing a total of eight children, aged from 4 weeks to 13 yr.1,8,28,29 Parke et al.1 reported five criti-
cally ill children who received propofol for > 90 h at a rate of > 5 mg kg h-1 and died. The 
high doses and long duration may explain these deaths. Regrettably, these case reports reveal 
no details on use of parenteral feeding. Bray2 reviewed propofol infusion in a PICU and found 
a significant association between long-term high-dose propofol infusion and the development
of progressive myocardial failure. However, full details on comorbidity and parenteral feeding 
are lacking. Bray,22,30,31 Cray et al.29 and Cravero (unpublished data) expressed concerns about 
propofol as a sedative in children. Strickland et al.32 reported an 11-year-old girl with an astro-
cytoma who died after long-term propofol infusion. However, a cause-and-effect relationship 
could not be determined. More recently, Koch et al.33 described a 5-year-old child receiving 
short-term propofol infusion at a high rate who developed lactic acidosis.
Based on 14 publications, describing 27 patients, and one unpublished trial, the US Food 
and Drugs Administration contraindicated propofol for sedation of children < 18 yr receiving 
intensive care.4 However, 17 other publications appeared in support of propofol, reviewing a 
total of 395 patients without evidence for a relationship between propofol infusion and death.
This paper describes a prospective cohort study comparing safety and efficacy of propofol
and midazolam in children < 2 yr. Clearly, our study has limitations. First, the number of 
children receiving propofol 6% in this study is too small to allow conclusions to be drawn. 
Reviewing the total of 422 children, described in the above publications with regards to safety, 
eight children (< 2%) had evidence of propofol infusion syndrome.3 Thus, to encounter one 
child with the propofol infusion syndrome, we would have had to include at least 50 patients 
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receiving propofol. Secondly, all studied children were healthy, apart from their major cranio-
facial deformities. Therefore these children are not representative of the general ICU popula-
tion. Thirdly, the children received low doses of propofol; higher doses might have produced 
adverse events. Fourthly, blinding was not possible in this study, because of propofol’s charac-
teristic consistency. Fifthly, randomization was aimed at but failed due to unforeseen logistic 
reasons.
Despite the limitations of our study, it is important to note that we did not encounter any 
problems using propofol 6% as a sedative with dosages less than 4 mg kg-1h-1 in children with 
a median age of 10 (IQR 3-17) months during a median period of 11 (6 to 18) h in postoperative 
patients without multiple organ failure or critical illness. Based on this study, it is too early to 
state that propofol is safe for sedation in children. However, we believe that it is important to 
share our experiences with propofol 6% and call for randomized controlled trials in pediatric 
patients to establish the safety of propofol as a sedative.
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Population model for propofol sedation in infants
Abstract
Background: To support safe and effective use of propofol in nonventilated children after 
major surgery, a model for propofol pharmacokinetics and pharmacodynamics is described.
Methods: After craniofacial surgery, 22 of the 44 evaluated infants (aged 3-17 months) in 
the pediatric intensive care unit received propofol (2-4 mg·kg-1 · h-1) during a median of 12.5 
h, based on the COMFORT-Behavior score. COMFORT-Behavior scores and Bispectral 
index values were recorded simultaneously. Population pharmacokinetic and pharmacody-
namic modeling was performed using NONMEM V (GloboMax LLC, Hanover, MD).
Results: In the two-compartment model, body weight (median, 8.9 kg) was a significant
covariate. Typical values were CL = 0.70 · (BW/8.9)0.61 l/min, Vc = 18.8 l, Q = 0.35 l/min and 
Vss = 146 l. In infants who received no sedative, depth of sedation was a function of baseline, 
postanesthesia effect (Emax model) and circadian night rhythm. In agitated infants, depth of 
sedation was best described by baseline, postanesthesia effect, and propofol effect (Emax 
model). The propofol concentration at half maximum effect was 1.76 mg/l (coefficient of
variation = 47 %) for the COMFORT-Behavior scale and 3.71 mg/l (coefficient of variation
=145%) for the Bispectral index.
Conclusion: Propofol clearance is two times higher in nonventilated healthy children than 
reported in the literature for ventilated children and adults. Based on the model, we advise a 
propofol dose of 30 mg/h in a 10 - kg infant to achieve values of 12-14 on the COMFORT-
Behavior and 70-75 on the Bispectral index during the night. Wide pharmacodynamic vari-
ability emphasizes the importance of dose titration.
Introduction
To correct craniosynostosis, most infants undergo surgery in the first years of life. Because of
edematous eyelids, separation from parents and the need to stay at the intensive care unit for 
control of vital signs, and the possible development of neurological sequelae, these children 
often experience stress postoperatively. Although propofol is widely used for sedation in the 
adult intensive care, its use is subject to debate in sedated children in the pediatric intensive 
care since the report of five deaths in children receiving high doses (> 5 mg · kg-1 · h-1) of 
propofol.1 In general, larger doses of propofol are required in children, and it is suggested 
that this is because of differences in pharmacokinetics,2 sensitivity,3 or both.
To date, there are no population models in children investigating the pharmacodynamics 
to study the variability between and within children. As a pharmacodynamic endpoint, 
a number of clinical sedation scores have been devised for use in children, in which the 
COMFORT-Behavior (COMFORT-B) scale4,5 would be a reliable alternative to the original, 
most used COMFORT scale.6 The Bispectral Index (BIS) may have benefits in comparison
with clinical sedation scores because it assesses sedation continuously and may provide an 
objective, quantitative measure of the level of sedation.7 However, to date, the BIS has only 
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been validated in children older than 1 yr.
Our clinical experiences regarding the use of propofol evaluated by COMFORT-B in young 
children in the pediatric surgical intensive care unit (PSICU) have recently been published 
by Prins et al.8 In the current article, propofol pharmacokinetics and pharmacodynamics 
characterized by use of the COMFORT-B and BIS on the postoperative sleep pattern in 
nonventilated infants are described using population modeling, to select appropriate doses 
in infants and to support the safe and effective use of propofol.
Materials and Methods
The study was performed in the PSICU of the Erasmus Medical Center – Sophia Chil-
dren’s Hospital, Rotterdam, The Netherlands. The study protocol was approved by the 
ethics committee of the Erasmus Medical Center – Sophia Children’s Hospital. Written 
informed consent was obtained from the parents. The studied infants, the design, sedative 
and analgesic regimen, and safety parameters are presented in detail in the article of Prins et 
al.8 and shortly repeated as relevant to this article.
Patients
Eligibility criteria included major craniofacial surgery, age between 1 month and 2 yr, and 
postoperative admitted to the PSICU. The children were randomly allocated to receive 
propofol or midazolam if sedative medication was judged necessary on the basis of the 
COMFORT-B score (score ≥ 17). Infants were excluded when they had respiratory infec-
tions, epilepsy, hypertriglyceridemia or family histories of hypercholesterolemia, or history 
of allergy to propofol, eggs or soybean oil.
Patient characteristics of the group in which no sedation was necessary (nonagitated group) 
and the group in which sedation was needed (agitated group) are presented in Table 1. 
Infants who received midazolam could be used for pharmacokinetic and pharmacodynamic 
analysis before midazolam administration if more than two COMFORT-B observations were 
available for the description of the postoperative sleep pattern in the agitated group. These 
infants are represented in table 1 as the agitated, no sedative group. All patients had normal 
hepatic and renal functions.
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Anesthesia
Standardized anesthesia was induced with thiopental (5 mg/kg) or sevoflurane and fentanyl
(2.5 μg/kg) and the infants were paralyzed with vecuronium (0.1 mg/kg). Thereafter, the 
infants underwent intubation and mechanical ventilation. Anesthesia was maintained with 
isoflurane, oxygen, and air, and fentanyl was given as needed. A median total dose of 17.9
(10.0-32.9) μg/kg fentanyl was administrated during surgery. Approximately 2 h before ex-
tubation, a loading dose of acetaminophen (40 mg/kg) was administered rectally. After the 
operation, the patients were admitted to the PSICU for a minimum of 24 h, depending on 
the clinical condition.
Sedative and Analgesic regimen
Pharmacodynamic data collection was started at arrival at the PSICU. The COMFORT-B 
score, which has been validated in pediatric intensive care, was used as a pharmacodynam-
ic endpoint.4,5 The COMFORT-B scale assesses six behavioral items: alertness, calmness, 
muscle tone, body movement, facial tension, crying (nonventilated children) or respiratory 
response (ventilated children). All items range from 1 (no distress) to 5 (severe distress), 
resulting in a total score varying from 6 to 30. The interobserver reliability represented by 
linearly weighted κ was greater than 0.65 for all nurses and the principal investigator. In 
addition, the BIS was recorded continuously and noted at 15-min intervals (BIS® A 2000 
version 3.12, Aspect Medical Systems, Natick, MA; with pediatric BIS® sensors). The BIS 
Agitated      Nonagitated
Propofol No sedative No sedative
Sex, M/F 15 / 7 8 / 5 5 / 4
Age, months 10 (3.8-17.3) 10.9 (3.2-18.5) 8.8 (4.0 – 12.4)
Weight, kg 8.9 (4.8-12.5) 9.3 (5.1-11) 8.3 (5.5 – 9.6)
Height, cm 71 (60-76) 72 (58-80) 70 (61.5-77)
CYP genotype
mutant frequencies
   2B6*1/*5
   2B6*1/*6
   2B6*6/*6
   2B6*1/*7
   2C9*1/*2
   2C9*1/*3
   2C19*1/*2









Infusion duration, h 12.5 (6.0-18.1) - -
Data are median (minimum-maximum).
Table 1 Patient characteristics of agitated infants and nonagitated infants.
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ranges from 100 (awake) to 0 (isoelectric electroencephalogram). Propofol 6% (Department 
of Clinical Pharmacy, St Antonius Hospital, Nieuwegein, the Netherlands9,10) was given by 
a central venous line into a running saline infusion by a B.Braun Medical infusion pump 
(Melsungen, Germany) to a summed rate of 3 ml/h. For propofol, the doses were increased 
or decreased as needed up to a maximum of 4 mg · kg-1 · h-1. When patients were inad-
equately sedated with 4 mg · kg-1 · h-1 propofol, midazolam was added. One patient received 
an additional dose of 0.1 mg/kg followed by 0.05 mg/kg midazolam, one patient received 
two doses of 0.1 mg/kg, and two patients a single bolus of midazolam. These responses 
were excluded from the analysis. To determine whether restlessness was induced by pain, 
the trained nurses also obtained the visual analog scale score. Patients received standard four 
daily doses of 120-240 mg acetaminophen rectally.11 In more than 99% of the observations, 
the visual analog scale score was less than 4.
Blood sampling
Arterial samples (250 μl) were taken before the start of the propofol infusion; at approxi-
mately 30 or 45, 60 or 90, and 120 min after the start of the propofol infusion; three times in 
steady state, just before and 1 h after dose adjustment; just before stopping; and 15 or 30, 45 
or 60, 120, and 150 min after the end of the infusion.
Analytical methods
Propofol concentrations were measured in whole blood using high-performance liquid 
chromatography with fluorescence detection as described in a previous study from our
laboratory.3,12 Blood samples were collected in oxalate tubes and stored at 4ºC until analysis 
(within 1 week). The limit of quantification was 0.035 mg/l, and the between-day coeffi-
cients of variation were less than or equal to 6.0%.
Genomic DNA was isolated from EDTA blood (MasterAmp; Epicenter Technologies, 
Madison, WI). Cytochrome P450 (CYP) 2B6 mutations 516G>T, 785A>G and 1459C>T 
were analyzed (alleles *4, *5, *6, *7 and *9). Polymerase chain reaction-restriction 
fragment length polymorphism analyses were performed as described previously13 with the 
exception of using BstNI as restriction enzyme instead of StyI. Analysis for the 1459C>T 
polymorphism was performed using primers 5’-CTGTTGCAGTGGACATTTG-3’ and 
5’-ATCTCACTCCTGCACTCAC-3’ in a polymerase chain reaction with an initial step of 
7 min 94ºC, followed by 30 cycles of (1 min at 94ºC, 1 min at 57ºC, 1 min at 72ºC) and 
concluded by a final extension step of 6 min at 72°C. The polymerase chain reaction product
was digested with BglII. CYP2C9*2, *3 and CYP2C19*2 and *3 analyses were performed 
on the LightCycler® (Roche Diagnostics, Mannheim, Germany), using the CYP2C9 and 
CYP2C19 kits (Roche Diagnostics), respectively.
Data analysis
The Non-Linear Mixed effect Modeling (NONMEM) program (version V; GloboMax LLC, 
Hanover, MD)14 was used for population analysis. S-plus (version 6.2; Insightful software, 
Seattle, WA) was used to visualize the data. NONMEM estimates the mean pharmacokinetic 
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and pharmacodynamic parameters of the population and the interindividual variability and 
the residual error, minimizing the objective function (-2 log likelihood). The NONMEM 
option of the first-order conditional estimation (method 1) with η-ε interaction was used.
Model development was performed in four steps: (1) choice of the structural pharmacoki-
netic or pharmacodynamic model, (2) choice of the residual model, (3) covariate analysis, 
and (4) internal validation of the model. Discrimination between different models was made 
by comparison of the objective function. A value of P < 0.005, representing a decrease of 
7.8 in the objective function, was considered statistically significant. In addition, the diag-
nostic plots (observed vs. individually predicted, observed vs. population predicted, time vs. 
weighted residuals, and population predictions vs. weighted residuals) for examining bias 
and precision, the confidence interval of the parameter estimates, the correlation matrix and
visual improvement of the individual plots were used to evaluate the model.
Covariate analysis
Covariates were plotted independently against the individual post hoc parameter estimates 
and the weighted residuals to identify their influence. Tested covariates were body weight,
age, body surface area, body mass index (if height was known), and sex. The pharmacoki-
netic parameters were also tested for correlation with heart frequency, blood pressure, tri-
glycerides, and the CYP isoforms ( 2B6*4, *5, *6, *7, *9, 2C9*2, 2C9*3, 2C19*2, 2C19*3). 
In addition, the influence of the total dose of fentanyl administration during surgery on the
pharmacodynamics was assessed.
Potential covariates were separately incorporated, and a significant covariate that most
reduces the objective function was left in the model. Additional covariates had to reduce this 
objective function further to be retained in the model. The choice of the model was further 
evaluated as discussed above.
Validation 
Bootstrap resampling method was used to assess the stability of the parameter estimates 
and the robustness of the final model.15 A bootstrap involves repeated random sampling to 
produce another data set of the same size but with a different combination of individuals. 
The mean parameter values and coefficients of variation (CVs) of the bootstrap replicates
were compared with the estimates of the original data set.
Pharmacokinetic model
The parameters of a two-compartment model were fitted to the log-transformed data, pa-
rameterized in terms of volume of steady state (Vss), volume of the central compartment 
(Vc), clearance (CL), and intercompartmental clearance (Q) using subroutine ADVAN 5. 




The individual value of the parameters of the ith subject was modeled by
(2)
where θmean is the population mean and ηi is assumed to be a Gaussian random variable 
with zero mean and variance ω2. The residual error was described with a proportional error 
model. This means for the jth observed log-transformed concentration of the ith individual 
the relation (Yij):
(3)
where cpred is predicted transformed propofol concentration and εij is a random variable with 
mean zero and variance σ2.
Simulation
To compare the pharmacokinetic results with previously published pharmacokinetic models, 
simulations were performed using the model developed by Knibbe et al.,3 Rigby-Jones et 
al.,16 and Schüttler and Ihmsen.17
Pharmacodynamic model
Depth of sedation was characterized with postoperative natural sleep pattern (PNSP) and 
propofol effect (PEF).
(4)
where Sij is the jth observed sedation level in the ith subject.
The postoperative natural sleep pattern (PNSP) was described as a function of three equations 
allowing the depth of sedation to increase and decrease during the first postoperative night
in the absence of a sedative.
(5)
In which BSL represents the level of sedation at arrival at the PSICU, PAEFF represents the 
postanesthesia effect, and CNR the circadian night rhythm.
For estimation of the interindividual variability of the baseline, log-normal distributions 
were assumed. This means for the ith individual:
(6)
where BSLmean is the population mean and ηi is a Gaussian random variable with zero mean 
and variance ω2.
Postanesthesia effect (PAEFF) was assumed to wash out in time postoperatively by an Emax 
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model, resulting in an decrease of the depth of sedation to a maximum estimated score (Smax) 
for the COMFORT-B and 100 (awake) for the BIS.
(7)
where PAEmax is the maximal effect from BSL to the maximal score Smax. TPS is the time 
(minutes) postsurgery, T50, PS is the time (minutes) postsurgery at half maximum postanesthe-
sia effect, and γ is the steepness of the time-versus-response relation. Interindividual vari-
ability of T50, PS and γ were assumed to be log-normally distributed.
Circadian night rhythm (CNR) was modeled by
(8)
where O denotes the onset of the natural night dip in minutes from 12.00 h. The end of the 
circadian night dip (wake-up time) was assumed at 7.00 h, because at this time point, the 
light is turned on, nursing care is optimized, and parents arrive at the PSICU. A (COMFORT-
B or BIS units) is the amplitude of the night dip, and 2 π / Fr (minutes) is frequency of the 
oscillations.
Propofol effect (PEF) was related to the pharmacokinetic model-predicted individual 
propofol concentration (Cij) by a simple Emax model:
(9)
where Emax,i is the maximum possible propofol effect (equal to Smax -6 on the COMFORT-
B scale and 100 on the BIS scale) in the ith subject, assuming that the response will reach 
the maximum effect at doses sufficiently higher than 4 mg · kg-1 · h-1 propofol. EC50 is the 
propofol concentration (mg/l) at half maximum effect, in which the interindividual variabili-
ty was assumed to be log-normally distributed. The residual error in the COMFORT-B score 
and BIS was best characterized by a proportional and an additive error model, respectively.
(10)
(11)




A median of 11 blood samples per infant were collected from 22 evaluable propofol patients. 
The pharmacokinetics of propofol were best described with a two-compartment model. In 
some of the patients, the central line had not been primed, for which we added a lag time 
(ALAG) for a subpopulation to the model to describe the delay of delivery. Body weight 
(median, 8.9 kg) incorporated as a power function was found to be a significant covariate for
elimination clearance, thereby reducing the interindividual variability (CV%) in clearance 
from 27% to 20%. A slope-intercept model or a weight-proportional model resulted in the 
Table 2 Parameter estimates of the basic pharmacokinetic model, the bodyweight power model and the stability of the 
















, l/min - 0.70 (5.3) 0.71 (6.6)
b - 0.61 (19.7) 0.59 (33.8)
V
SS
, l 144 (32.1) 146 (31.2) 148 (32.0)
Q, l/min 0.34 (11.9) 0.35 (11.0) 0.35 (11.1)
V
c
, l 20.3 (27.9) 18.8 (30.0) 16.8 (46.0)
ALAG
1
, min 0 0 -
ALAG
2
, min 40.20 (3.1) 40.20 (3.0) 38.10 (16.3)
Fraction (ALAG) 0.52 (24.1) 0.52 (24.3) 0.47 (31.1)
Interindividual variability, %
CL 27 (44.9) 20 (40.0) 20 (48.3)
V
SS
136 (34.6) 145 (38.4) 126 (44.8)
CLV
SS
49 (34.0) 49 (29.3) 43 (33.4)
Residual error, %
ε 37 (21.0) 37 (20.7) 36 (20.4)
Performance measures
-2LL -141.5 -155.8 -176.2
CV, coefficient of variation of the parameter values; BS, bootstrap validation; CL, clearance in an individual; CL
std
, clearance in 
a standardized individual of 8.9 kg; b, power scaling parameter; V
ss
, volume of steady state; Q, intercompartmental clearance; 
V
c
, central volume (related to V
ss
); ALAG, lag time of delivery; Fraction, fraction of the population with ALAG=0; interindividual 
variability, square root of the exponential variance of η minus 1; ε, residual error proportional calculated as square root of the 
variance; -2LL, objective function.
47
Population model for propofol sedation in infants
same decrease in objective function. The addition of other covariates (arterial blood pressure, 
heart frequency, triglycerides, CYP isoforms [2B6 *5, *6, *7, 2C9*2, 2C9*3, 2C19*2], age, 
body mass index, body surface area and sex) to the model did not improve the quality of 
fit. The pharmacokinetic parameter values and precision of the basic model, the bodyweight
power-adjusted model, and the values obtained from the bootstrapping are shown in Table 
2. The fits of 250 bootstrap replicates of the data set demonstrated the stability of the model.
Individual fits of the model for a median situation and the most biased situation of the final
model (bodyweight power model) to the observed data are shown in Figure 1.
Figure 1 Log-transformed propofol concentration versus time for a median (A) and the worst (B) performance of the 
final pharmacokinetic bodyweight power model. The solid circles represent measured propofol concentrations, the 
solid lines represent the individual predicted concentrations, and the dashed lines represent the population predicted 
concentrations.














































Figure 2 Simulated population propofol concentrations (line) versus observed concentrations (solid circles) in an infant 
aged 10 months and weighting 10 kg, after continuous infusion of 18, 24, 30 and eventually up to 42 mg/h. The simula-
tions were based on the current study (solid black line) and published pharmacokinetic models in ventilated children 
after cardiac surgery (dashed line)3 (dashed and dotted line)16 and during anesthesia (solid gray line).17 
























The simulations using the pharmacokinetic model previously developed by Knibbe et al.,3 
Rigby-Jones et al.,16 Schüttler and Ihmsen17 overestimated the observed propofol concentra-
tions in our patients (Figure 2), indicating that the pharmacokinetics in our study population 
of awake children are distinctly different.
Pharmacodynamics
The total data set included a median of 15 (3-25) COMFORT-B scores and 73 (3-101) BIS 
observations per infant from 21 propofol patients, 9 natural sleep patients who received no 
sedative, and 13 natural sleep patients until midazolam administration. Table 3 summarizes 
the estimated pharmacodynamic parameters for the full model (postoperative natural sleep 
pattern and propofol effect) for the COMFORT-B and the BIS. All infants arrived comfort-
able and lightly sedated at the PSICU (BSL), starting with a COMFORT-B score of 10.4 (CV 
16%) and a BIS value of 79 (CV 7%). In the agitated infants during the postoperative night, 
the narcotic effect washed out earlier, indicated by a smaller T50,PS (518 vs. 1580 minutes for 
the COMFORT-B and 1044 vs. 2052 min for the BIS). The steepness value of the washout 
effect (γ) for the BIS was 8, whereas the steepness for the COMFORT-B was not found to 
be significantly different from 1. During the night, the infants were “deeper” asleep, which
was implemented in the model using the dip of a circadian rhythm. The start of the dip was 
estimated at 20.00 h (equal to 480 min from 12.00 h) on the COMFORT-B with an amplitude 
of 3.5 units and 17.30 h (equal to 330 min) on the BIS with an amplitude of 14.5. For the 
agitated infants receiving propofol during the night, a night dip could not be estimated. 
Propofol was started at a median time of 19.00 h, which is equal to 5.5 h after surgery. 
The induced BIS depression as a function of the propofol concentration showed consider-
able intersubject variability (CV 145%). The bootstrap validation (100 times) confirmed
the precision of the parameters. Figure 3A shows a median fit of a nonagitated infant who
received no sedative, with a reduction in response during the night. Figure 3B and C show 
a median and a worse fit of the sleep pattern of an agitated infant and the influence of
propofol. Figure 4 illustrates the simulated relation among time, propofol infusion rate, 
propofol concentration, and predicted population response in terms of depth of sedation 
using COMFORT-B and BIS. The difference between a 10-kg infant and a 5-kg infant is 
shown at the infusion rate of 18 mg/h. The difference in postoperative natural sleep pattern 
between infants who did or did not become agitated is shown at the propofol infusion rate 
of 0 mg/h.
There was not enough evidence to support sex, age, bodyweight, and total dose of fentanyl 
during surgery as covariates on the pharmacodynamic parameters.
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Table 3 Pharmacodynamic parameter estimates of the depth of sedation postoperatively using COMFORT-B and BIS and 











BSL 10.4  (5.1) 10.4 (5.6) 79.2 (1.2) 78.9 (1.1)
PAEFF T
50,PS
, min, agitated 518 (44.2) 548 (49.7) 1044 (7.1) 1048 (10.8)
T
50, PS
, min, nonagitated 1580 (46.3) 1694 (49.9) 2052 (24.3) 2106 (41.5)
γ 1 Fixed - 8.3 (27.3) 9.7 (46.3)
Maximal score S
max
20.0 (25.1) 19.7 (28.5) 100 Fixed -
CNR Onset, min 480 (1.2) 376 (42) 330 (0.8) 323 (11.8)
Frequency, min 1390 (8.6) 1752 (38.4) 2440 (20.3) 2796 (31.1)
Amplitude,
response units
3.5 (36.7) 3.7 (33.7) 14.5 (16.2) 16.8 (18.7)
PEF EC
50
, mg/l 1.76 (28.4) 2.01 (38.7) 3.71 (31.3) 4.01 (38.0)
Interindividual variability, %
BSL 16 (33.6) 15 (37.1) 7 (22.7) 7 (18.9)
T
50,PS
- - 23 (48.0) 29 (55.0)
γ - - 115 (48.3) 103 (65.9)
EC
50




, % 32 (8.1) 32 (8.1) - -
ε
2, 
BIS units - - 13 (6.0) 13 (6.5)
Performance measures
-2LL 2470.9 2446 16497 16430
CV, coefficient of variation of the parameter values; COMFORT-B, COMFORT-Behavior score; BIS, Bispectral index; BS, bootstrap 
validation; BSL, level of sedation at arrival; PAEFF, postanesthesia effect; T
50,PS
, time post surgery at half maximum postanaesthesia 
effect; γ, steepness; CNR, circadian night rhythm; PEF, propofol effect; EC
50
, propofol concentration at half maximum effect;
interindividual variability, square root of the exponential variance of η minus 1; ε
1
 , residual error proportional; ε
2
 , residual error 
additive; -2LL, objective function.
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Figure 3 COMFORT-Behavior score (COMFORT-B; left column) and Bispectral index (BIS; right column) versus time 
(minutes) from 12.00 h for a median performance in the nonagitated group (A) and a median (B) and worse (C) perfor-
mance in the agitated group receiving propofol. The solid circles represent the observations, the solid lines represent the 
individual predicted observations, and the dashed lines represent the population predicted observations. The gray line 
represents the individual predicted propofol concentrations.
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Figure 4 Simulated representation of the relation between time (minutes) from 12.00 h, propofol administration 
(0, 18, 30, and 36 mg/h), population predicted propofol concentration (dashed line) and population predicted response 




To support safe and effective use of propofol during the first night after major surgery in
nonventilated infants younger than 1.5 yr, a population model for the influence of propofol
pharmacokinetics and pharmacodynamics on the depth of sedation was described, assessed 
using COMFORT-B and BIS.
Clearance in postsurgical healthy nonventilated infants was found to be two times higher 
than reported in the literature for ventilated children and adults.3,16,17 Based on the pharmaco-
kinetic model, propofol doses must be doubled in this pediatric group to obtain similar blood 
concentrations. We believe that the higher estimate of the CL (0.70 l/min) in an infant with 
a bodyweight of 8.9 kg (2.64 l/min standardized to an adult of 70 kg) in our study compared 
with 0.27 l/min (0.030 l · kg-1 · min-1) reported in the literature can partly be explained by 
the effect of the surgery and the condition of the patients. Rigby-Jones et al.16 found that 
patients aged 1 week to 12 yr undergoing cardiac surgery had reduced values for metabolic 
clearance (-26%). Cardiac patients in general show a reduced cardiac output, which may 
effect the propofol elimination because the clearance of propofol (a high-extraction drug) 
is dependent on liver blood flow. In addition, mechanical ventilation may be of influence
on the clearance of propofol. In patients with trauma and those in the surgical intensive 
care unit, increasing the positive end-expiratory pressure during mechanical ventilation has 
been shown to decrease total hepatic blood flow18. Murat et al.2 reported a large clearance 
of 0.44 l/min (0.049 l · kg-1 · min-1) in spontaneously breathing children aged 1-3 yr with 
minor burns after a single dose of 4 mg/kg. Healthy ventilated children undergoing anesthe-
sia did show a lower estimate of the clearance.17,19 The model developed by Schüttler and 
Ihmsen17 for healthy ventilated children undergoing anesthesia from 2 yr of age showed less 
overprediction of the blood concentration than the model developed by Knibbe et al.3 and 
Rigby-Jones et al.16 for ventilated children after cardiac surgery. They also found a smaller 
value of the central volume compared to our model (5-12 l vs. 19 l), which may be a con-
sequence of the relation of the central volume to the volume of distribution of steady state. 
Bodyweight partially explained the interpatient variability in CL. The influence of a slope-
intercept model, a proportional model, or a power model with a power scaling parameter of 
0.61 on the clearance was comparable in the range of 4.8-12.5 kg. We choose for the power 
model because an allometric three-fourths power model has been used with success for in-
terspecies scaling.20 As with other studies, age was not found to be a significant covariate.16,21 
In addition, the genetic expression of the investigated CYP isoforms did not explain the 
interindividual differences in the clearance. 2B6 would be predominantly involved and, at 
a lower rate, 2C9 and 2C19 in the minor metabolic hydroxylation pathway.22 The homoge-
neous patient characteristics and the relatively small number of patients may account for the 
unexplained interpatient variability.
The large pharmacodynamic interindividual variability and residual error in BIS and 
COMFORT-B emphasize the complexity of depth of sedation in infants. Young children 
can vary in depth of sedation in the absence of sedatives as a result of day-night rhythm, 
the presence of parents and medical staff, hunger, light and noise.5,23 Especially at lighter 
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sedation levels, noise has a greater effect on the BIS.24 To account for natural variation, data 
of infants not receiving a sedative and until sedative administration were used to describe 
a postanesthesia effect (PAEFF) and a night dip (CNR). For adults, a similar PAEFF has 
been described after coronary artery bypass grafting by assuming a virtual drug that washes 
out over time.25 Because stress and severe discomfort entail risks, a complete natural sleep 
pattern of agitated infants could not be described. The administration of the sedative may 
cover the night dip, which could not been estimated in the agitated children. The EC50 of 
propofol for the reduction of the BIS was different from that of the COMFORT-B, indicat-
ing that the two measurements are not interchangeable measures of the propofol effect in a 
spontaneously breathing child. Courtman et al.26 and Crain et al.27 also suggest that BIS and 
COMFORT are only moderately correlated: A child can be comfortable, but fully awake. 
The use of the BIS has the advantage that it assesses sedation continuously and may allow 
more objective assessment of sedation. It gives additive information and can be useful for 
patients who are difficult to assess clinically. The use of the maximal estimated score of
20 on the COMFORT-B scale and a smaller number of observations make it difficult to
determine which sedation scale is more sensitive in this population based on the EC50, but 
in lightly sedated children, the COMFORT-B seems more advantageous. The COMFORT-B 
has never been used before as a pharmacodynamic instrument in a pharmacokinetic-pharma-
codynamic propofol analysis, but the effect of propofol on BIS in adults has been described. 
Interestingly, the sensitivity of infants to propofol, defined as EC50, seems comparable to 
that in adults. Defining the Emax as the maximum effect seen on the BIS, Bouillon et al.
28 
estimated an EC50 of 3.07 mg/l (CV 12.1%) and Doufas et al.
29 estimated a value of 2.4 mg/l 
(CV 30%). By fixing the Emax to 100, Calvo et al.
30 estimated the EC50 on 3.91 mg/l (41%), 
which may suggest that infants only require higher doses because of differences in pharma-
cokinetics rather than pharmacodynamics. In general, the sensitivity to propofol between 
infants is quite variable. Unfortunately, no explanation could be found based on patient 
characteristics as age, bodyweight and sex. In this narrow age group, the potential stressful 
environment resulting from inability to see, separation from parents, and unknown voices 
may play a major role.
Based on the population pharmacodynamic model, we advise a propofol infusion rate of 
30 mg/h for a 10-kg nonventilated infant to achieve a COMFORT-B score between 12 and 
14, 6 h after surgery during the night, which corresponds to BIS values of 70-75 (Figure 4). 
The considerable variability emphasizes the importance of drug titration to a maximum of 
4 mg · kg-1 · h-1. Further pharmacodynamic studies in larger groups of children are needed 
to explain the variability in response and help clinicians to improve individualization. For 
drugs such as propofol, this is especially important because of the troublesome reports in the 
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Pharmacokinetics and effect of midazolam in infants
Abstract
Background: Because information on the optimal dose of midazolam for sedation of non-
ventilated infants after major surgery is scant, a population pharmacokinetic and pharmaco-
dynamic model is developed for this specific group.
Methods: Twenty-four of the 53 evaluated infants (aged 3-24 months) admitted to the 
Pediatric Surgery Intensive Care Unit, who required sedation judged necessary on the basis 
of the COMFORT-Behavior score and were randomly assigned to receive midazolam, were 
included in the analysis. Bispectral index values were recorded concordantly. Population 
pharmacokinetic and pharmacodynamic modeling was performed using NONMEM V 
(GloboMax LLC, Hanover, MD).
Results: For midazolam, total clearance was 0.157 l/min, central volume was 3.8 l, peripheral 
volume was 30.2 l, and intercompartmental clearance 0.30 l/min. Assuming 60% conversion 
of midazolam to 1-OH-midazolam, the volume of distribution for 1-OH-midazolam and 
1-OH-midazolamglucuronide was 6.7 and 1.7 l, and clearance was 0.21 and 0.047 l/min, 
respectively. Depth of sedation using COMFORT-Behavior could adequately be described 
by a baseline, postanesthesia effect (Emax model) and midazolam effect (Emax model).The 
midazolam concentration at half maximum effect was 0.58 μmol/l with a high interindividual 
variability of 89 %. Using the Bispectral index, in 57% of the infants the effect of midazolam 
could not be characterized.
Conclusion: In nonventilated infants after major surgery, midazolam clearance is two to five
times higher than in ventilated children. From the model presented, the recommended initial 
dosage is a loading dose of 1 mg followed by a continuous infusion of 0.5 mg/h during the 
night for a COMFORT-Behavior of 12-14 in infants aged 1 yr. Large interindividual vari-
ability warrants individual titration of midazolam in these children.
Introduction
Midazolam is one of the most commonly used agents for sedation in the pediatric intensive 
care unit (PICU) and has been studied in children and neonates requiring mechanical 
ventilation1,2,3 and in children when given as oral premedication.4,5 Moreover, midazolam 
can also be an adjuvant in the care of nonventilated infants admitted to the PICU, e.g., after 
craniosynostosis when the development of edematous eyelids postoperatively adds an extra 
stressful stimulus to the physical and emotional distress and discomfort that young children 
often encounter in the PICU.6 However, in this postoperative population of nonventilated 
infants aged younger than 1 yr, information about pharmacokinetics and pharmacodynamics 
of intravenous continuous infusion is scant. According to the literature, the optimal dose of 
midazolam may vary depending on hepatic blood flow, which is affected by mechanical ven-
tilation, hepatic and renal function, or change in enzyme activity of the cytochrome P450 3A 
subfamily during the first year of age.7,3,8,9 Midazolam is hydroxylated by CYP3A4/5 and, to 
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a lesser extent, by CYP3A7 in the major metabolite 1-OH-midazolam,10 which is as potent 
as the parent drug,11,12 and the minor metabolites 4-OH-midazolam and 1,4-OH-midazolam. 
The metabolites are rapidly converted to their glucuronide conjugates and excreted in the 
urine.
To date, the pharmacokinetic and pharmacodynamic relation of midazolam in infants has not 
been fully characterized.13
In this study, we describe a population pharmacokinetic and pharmacodynamic model for 
midazolam in nonventilated children after major craniofacial surgery using the validated 
pediatric clinical sedation score COMFORT-Behavior (COMFORT-B).14,15 Secondly, 
the Bispectral Index (BIS)16,17 is explored as a pharmacodynamic endpoint whose value 
in children in the PICU is still unclear. In the models, intraindividual and interindividual 
variabilities in concentration and effect are characterized, and the effect of covariates 
influencing interpatient variability is explored to develop an optimal dose scheme for
midazolam in nonventilated postoperative infants.
Materials and methods
The study was performed in the Pediatric Surgery Intensive Care Unit (PSICU) of the 
Erasmus Medical Center – Sophia Children’s Hospital, Rotterdam, the Netherlands. The 
study protocol was approved by the ethics committee of the Erasmus Medical Center – 
Sophia Children’s Hospital. Written informed consent was obtained from the parents. The 
studied patients and the design of the randomized study are presented in detail in the article 
of Prins et al.,18 in which the safety assessments in the patients receiving midazolam and 
propofol are described and shortly repeated in the article of Peeters et al.,19 in which the pop-
ulation pharmacokinetic and pharmacodynamic model for the children allocated to receive 
propofol is described. For brevity, parts of the methods are mentioned in this article when 
relevant.
Patients
Data of children who required sedative medication (agitated group) according to the 
COMFORT-B score (score ≥ 17) and who were randomly allocated to receive midazolam 
were included in the analysis. Criteria for eligibility in the study included age between 1 
month and 2 yr; admission to the PSICU after major craniofacial surgery; and no respira-
tory infections, epilepsy, hypertriglyceridemia or family histories of hypercholesterolemia, 
or allergic history to midazolam, propofol, eggs or soybean oil. Characteristics of patients 
in the midazolam group are shown in Table 1. The median age was 11.1 (3.2-24.7) months, 
and the median weight was 9.4 (5.1-12) kg. For the description of the postoperative sleep 
pattern of the agitated group, we also included in the analysis data from 20 infants (14 
male, 6 female; age, 9.4 [3.8-17.3] months; weight, 8.8 [4.8-12.5] kg) who were randomly 
assigned to receive propofol for whom more than two COMFORT-B observations before 
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Patient Sex, M/F Age, months Weight, kg Height,  cm
Infusion 
duration, h
1 M 12.3 10 - 12.2
2 M 11.2 10.5 - 16.7
3 M 11.7 9.4 71 12.0
4 F 11.5 9.5 72 11.9
5 M 18.5 8.4 - 10.9
6 M 4.8 6.3 - 10.3
7 F 24.7 12 92 14.8
8 M 12.6 12 - 16.3
9 M 10.5 11 - 14.6
10 M 15.4 10 - 11.8
11 M 4.2 6.7 - 16.0
12 F 12.1 9.3 78 14.9
13 M 9.3 8.1 68 16.2
14 F 3.2 5.1 - 13.9
15 F 3.4 6.5 58 14.9
16 F 14 11.5 78 14.8
17 F 10.2 7 67 0.0
18 M 10.9 8 - 4.5
19 F 4.9 7.5 61.5 13.3
20 M 6.5 7.6 69 4.0
21 M 11.0 9.6 75 10.9
22 M 9.2 9.8 73.5 10.6
23 M 11.7 11 - 16.0
















Table 1 Patient characteristics of agitated infants who received midazolam.
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propofol administration were available. In 9 infants (5 male, 4 female; age, 8.8 [4.0 – 12.4] 
months; weight, 8.3 [5.5 – 9.6] kg), no sedation was necessary (nonagitated group). One 
infant received a bolus of midazolam at the end of the operation, before entering the PSICU. 
During the stay in the PSICU, no sedation was needed. In contrast to Prins et al.,18 this 
particular infant was included in the midazolam group in stead of the group in which no 
sedation needed. All were full-term babies without overt growth retardation. All patients had 
normal hepatic and renal functions. Genotype analysis identified 22 carriers of the CYP3A5
allele among the 24 infants who received midazolam (2 heterozygous CYP3A5*1/*3, clas-
sified as extensive metabolizers, and 20 homozygous CYP3A5*3/*3, classified as poor me-
tabolizers), and in 2 infants, no result was obtained. Three carriers of the CYP3A7*1C were 
identified (3 heterozygous). The allele CYP3A4*1B was not detected.
Sedative and analgesic regimen
From arrival at the PSICU, depth of sedation was evaluated using the COMFORT-B score, 
which rates six behavioral items.20,14 Alertness, calmness, muscle tone, body movement, 
facial tension, crying (nonventilated children), or respiratory response (ventilated children) 
are scored on a five-point scale, resulting in a total score varying from 6 (no distress) to
30 (severe distress). The interobserver reliability proved to be good for all nurses and the 
principal investigator (κ > 0.65). In addition, the BIS was recorded continuously and noted 
at 15-min intervals (Bispectral® A 2000 version 3.12; Aspect Medical Systems, Natick 
MA, with pediatric BIS® sensors). The BIS ranges from 100 (awake) to 0 (isoelectric 
electroencephalogram). Midazolam was initially given as 0.1 mg/kg bolus followed by a 
continuous infusion of 0.05 mg · kg-1 · h-1, titrated up after an additional bolus or down 
by 0.025 mg · kg-1 · h-1. In 21% of the infants, the starting dose was insufficient. To determine
whether restlessness was induced by pain, the trained nurses also obtained the visual analog 
scale. Patients received standard four daily doses of 120-240 mg acetaminophen rectally 
in the PSICU after a loading dose of 40 mg/kg rectally 2 h before extubation during the 
operation.21
Blood sampling
Arterial blood samples (500-1000 μl) were collected in each infant at the following times: at 
baseline before the start of the midazolam bolus, approximately 45 or 30 min, 90 or 60 min, 
120 min, 4 h, 6 or 8 h, and 10 h after the start of the midazolam infusion, just before and 1 h 
after dose adjustment, just before discontinuation of the midazolam infusion, and 30 or 45, 
60 or 90, 120 and 180-240 min after the end of the infusion (median of 11 samples per child). 
If the arterial line was no longer available (dislocation, obstruction), venous samples were 
collected from a central line, routinely present in the superior caval vein. In five infants,
venous blood samples were obtained with three, three, five, eight, and nine venous samples
taken per infant, respectively. After collection, the samples were centrifuged and stored at 
-80ºC until analysis.
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Analytical methods
Midazolam, 1-OH-midazolam and 1-OH-midazolamglucuronide concentrations were 
measured in serum using high performance liquid chromatography with ultraviolet detection 
at 230 nm. The mobile phase was prepared as follows: 400 µl phosphoric acid, 85%, and 146 
µl triethylamine were added to 530 ml water. The pH was adjusted to 3.2 with 10% potassium 
hydroxide, and 470 ml acetonitrile was added. Temazepam was used as an internal standard. 
Borate buffer, 500 μl, 0.05 M (pH 9.2), was added to 200 μL serum. Following liquid-
liquid extraction with 6 ml dichloromethane, the organic layer was evaporated to dryness 
at 37ºC. The residue was reconstituted in 200 μl of mobile phase, and 75 μl was injected 
onto the analytical column (Lichrosphere 100RP-18 encapped 5 µm; Merck, Darmstadt, 
Germany). Total (conjugated and unconjugated) drug concentrations of 1-OH-midazolam 
were measured after enzymatic hydrolysis of 200 μl serum with 100 UI β-glucuronidase 
(Roche Diagnostics, Almere, The Netherlands) for 24 h at 37ºC. The differences between 
total and unconjugated 1-OH-midazolam concentration was taken as the 1-OH-midazolam-
glucuronide concentration. The limits of quantification were 11 μg/l for midazolam and 6
μg/l for 1-OH-midazolam using 200 μl of serum. Interassay and intraassay coefficients of
variation were less than 8 % and 13 %, respectively. Total recovery was larger than 90% for 
both compounds.
Providing data for a large genomic study, DNA was isolated from EDTA blood (MasterAmp; 
Epicenter Technologies, Madison, WI). CYP3A4*1B, CYP3A5*3, and CYP3A7*1C 
analyses were performed, using polymerase chain reaction restriction fragment length poly-
morphism assays, as described previously.22,23,24
Data analysis
The analysis was performed in NONMEM (Non-Linear Mixed effect Modeling; version V, 
release 1.1; GloboMax LLC, Hanover, MD)25 by use of the first-order conditional estimation
(method 1) with η-ε interaction. S-plus (version 6.2; Insightful software, Seattle, WA) was 
used to visualize the data. Population pharmacokinetic and pharmacodynamic data were 
sequentially analyzed. Discrimination between different models was made by comparison of 
the objective function. A value of P < 0.005, representing a decrease of 7.8 in the objective 
function, was considered statistically significant. In addition, goodness-of-fit plots (observed
vs. individually predicted, observed vs. population predicted, time vs. weighted residuals, 
and population predictions vs. weighted residuals) were used for diagnostic purposes. Fur-
thermore, the confidence interval of the parameter estimates, the correlation matrix, and
visual improvement of the individual plots were used to evaluate the model.
Covariate analysis
Covariates were plotted independently against the individual post hoc parameter estimates 
and the weighted residuals to visualize potential relations. The following covariates were 
tested: body weight, age, body surface area, body mass index, sex, and sampling (venous 
or arterial). The pharmacokinetic parameters were also tested for correlation with heart 
frequency, blood pressure, and the genotypes (CYP3A4*1B, 3A5*3, 3A7*1C). Potential co-
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variates were separately entered into the model and statistically tested by use of the objective 
function. A significant covariate that most reduces the objective function was left in the
model. Additional covariates had to reduce this objective function further to be retained in 
the model. The choice of the model was further evaluated as discussed previously.
Validation 
The internal validity of the population pharmacokinetic and pharmacodynamic models 
was assessed by the bootstrap resampling method (repeated random sampling to produce 
another data set of the same size but with a different combination of individuals). Parameters 
obtained with the bootstrap replicates were compared with the estimates obtained from the 
original data set.
Pharmacokinetic model
Midazolam and metabolite data were fitted simultaneously, and concentrations were
expressed as μmol/l. The molecular weights of midazolam, 1-OH-midazolam, and 1-OH-
midazolamglucuronide are 325.77, 341.77, and 517.9, respectively. The pharmacokinetic 
model used is schematically depicted in Figure 1. The midazolam data were described with 
a two-compartment model, parameterized in terms of volume of the central compartment 
(V1), volume of the peripheral volume (V2), intercompartmental clearance (Q), and clear-
ances to 1-OH-midazolam (CL1) and other metabolites (CL0). In the absence of information 
on the ratio of metabolite formation in children, CL1 was assumed to be 60% of the elimina-
Figure 1 Schematic representation of the pharmacokinetic model 
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tion clearance of midazolam CLe (the sum of CL0 and CL1) as reported in the literature for 
adults.1,10,26 The formation of 1-OH-midazolam and 1-OH-midazolamglucuronide was best 
described with a one-compartment model. CL3 is the clearance of 1-OH-midazolam, and 
CL4 the clearance of 1-OH-midazolamglucuronide. The volume of distribution of 1-OH-
midazolam (V3) was modeled as a fraction of the sum of V1 and V2 of midazolam, because 
estimation of this parameter was found to be unstable by the bootstrap resampling. The indi-
vidual value (post hoc value) of the parameters of the ith subject was modeled by 
(1)
where θmean is the population mean and ηi is assumed to be a gaussian random variable with 
zero mean and variance ω2. The intraindividual variability was best described with a combined 
additive and proportional error model for midazolam assuming a constant coefficient of
variation over the complete concentration range superimposed on a constant absolute error 
(equation 2) and a proportional error model for the metabolites (equation 3), respectively. 
This means for the jth observed concentration of the ith individual, the relation (Yij):
(2)
(3)
where cpred is predicted midazolam or metabolite concentration and ε1,2,3,ij are random variables 
with mean zero and variance σ2.
Pharmacodynamic model
Depth of sedation (S) was characterized as a function of postoperative natural sleep pattern 
(PNSP) and midazolam effect (MEF):
(4)
The PNSP was described as a function of three equations:
(5)
In which BSL is the level of sedation at arrival at the PSICU, PAEFF the postanesthesia 
effect, and CNR is the circadian night rhythm. 
The postanesthesia effect was assumed to wash out in time postoperatively by an Emax 
model, resulting in a more awake sedation level to a maximum estimated score (Smax) for the 




where PAEmax is the maximal effect from BSL to the maximal score Smax. TPS is the time 
(minutes) postsurgery, and T50, PS is the time (minutes) postsurgery at half maximum postan-
esthesia effect. Incorporation of the postanesthesia effect of the COMFORT-B score resulted 
in a reduction of the objective function by 80.1 points, which was highly significant.
Circadian night rhythm was modeled by
(7)
in which O denotes the onset of the natural night dip in minutes from 12.00 h. The end of 
the circadian night dip (wake-up time) was assumed at 7.00 h, because at this time point, 
the light is turned on, nursing care is optimized,and the parents arrive at the PSICU. A is 
amplitude of the night dip (units COMFORT-B or BIS), and 2 π / Fr is frequency of the os-
cillations (minutes). Introduction of the CNR improved the goodness of fit as reflected in a 
decrease in objective function of 18.9 points for the COMFORT-B and 119.3 points for the 
BIS.
Midazolam effect (MEF) was related to the pharmacokinetic model-predicted individual 
midazolam concentration (C1,ij) by a simple Emax model:
(8)
where Emax,i is the maximum possible midazolam effect (equal to Smax -6 on the COMFORT-
B scale and 100 on the BIS scale) in the ith subject. EC50 is the concentration (μmol/l) at half 
maximum effect, in which the interindividual variability was assumed to be log-normally 
distributed. The significant increase in objective function when the midazolam effect
is eliminated from the COMFORT-B and BIS model (50.3 and 119 points, respectively) 
demonstrated the effect of midazolam.
Using the BIS, EC50 was modeled with the MIXTURE subroutine in NONMEM (P < 0.005). 
A mixture model assumes that the population consists of two or more subpopulations, each 
approximating a normal distribution, where each subpopulation may have its own model. 
The ratio of the fraction and the corresponding typical EC50 are estimated, and NONMEM 
assigned patients to one of the subpopulations. 
For the influence of the active metabolite 1-OH-midazolam (C2,ij) in the presence of the 
midazolam concentrations (C1,ij), an additive interaction model was tested, in which the 
maximal effect (Emax) of midazolam and 1-OH-midazolam was assumed to be equal and the 
Hill factor was 1 for the two compounds:
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(9)
Because all infants had a normal renal function, the metabolite 1-OH-midazolamglucuro-
nide, which is only of clinical relevance in renal failure when accumulation occurs,27 was 
assumed to be without effect. The interindividual variabilities (ηis) were symmetrically dis-
tributed zero-mean random variables with a variance ω2. The intraindividual variabilities in 
the COMFORT-B (equation 10) and BIS (equation 11) were best characterized by a propor-
tional and an additive error model, respectively.
(10)
(11)




The pharmacokinetic model was derived from a median of 9 midazolam, 8 1-OH-midazolam, 
and 8 1-OH-midazolamglucuronide observations obtained per infant. Median 1-OH-
midazolam/midazolam and (1-OH-midazolam + 1-OH-midazolamglucuronide)/midazolam 
ratios were 0.37 in 158 samples and 2.3 in 144 samples, respectively. The pharmacokinetic 
parameter values and their confidence interval and the values obtained from the bootstrap-
ping are shown in Table 2. The fits of 250 bootstrap replicates of the data set demonstrated the
stability of the model. These mean parameter estimates were within 17% of those obtained 
with the original data set. However, it should be noted that the estimated volume of distribu-
tion of the metabolites must be taken with caution, because accurate estimates can only be 
obtained by separate administration and are affected by the assumed fraction of midazolam 
metabolized to 1-OH-midazolam. One individual who needed up to 0.2 mg · kg-1 · h-1 
midazolam showed very low midazolam and 1-OH-midazolam concentrations (two and five
times lower, respectively, as compared with the population mean), indicated by a high indi-
vidual CL1 (0.18 l/min) and CL3 (0.59 l/min) and a low 1-OH-midazolam/midazolam ratio 
of 0.18. Considering the large effect of this individual on the variability, an extra factor (fa) 
was estimated for this infant, which resulted in a significant decrease in objective function
(P < 0.001). This infant was heterozygous for the allele CYP3A7*1C. Figure 2 shows the 
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diagnostic plots for parent midazolam pharmacokinetic data. A representative example of 
measured and predicted serum concentrations of midazolam and its two metabolites for a 
median fit are shown in Figure 3. None of the explored covariates (body weight, age, body
surface area, body mass index, sex, heart frequency, blood pressure, sampling [venous or 
arterial] and the genotypes [CYP3A4*1B, 3A5*3, 3A7*1C]) were identified as significant,
although there was a trend towards a positive linear correlation between age and elimination 
clearance (Figure 4). In this figure, the appearance of the allele expression is also given.
Pharmacodynamics
The data set included 632 COMFORT-B observations from 53 infants, yielding a median 
of 13 (3-25) observations per infant and a total of 3570 BIS observations, 75 (4-496) per 
infant. The population parameters of the pharmacodynamic model are reported in Table 3. 
The bootstrap validation (100 times) confirmed the precision of the parameters. Age was
found to be a significant covariate for the baseline BSL (state of comfort at arrival) in the
PSICU, according to a slope-intercept model centered to the median value. Nonagitated 
Figure 2 Diagnostic plots for parent midazolam pharmacokinetic model, allowing the evaluation of the optimal model to 
the data. (A) Observed versus individually predicted midazolam concentrations. (B) Observed versus population predicted 
concentrations. (C) Weighted residuals versus time. (D) Weighted residuals versus population predictions. Solid lines 
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infants, in whom sedative administration was not necessary (COMFORT-B < 17), displayed 
a delayed postanesthesia washout (T50,PS 1794 vs. 537 min). In addition, they showed a night 
dip (CNR), which was implemented in the model using the dip of a circadian rhythm. The 
nighttime observations decreased a maximum of 3.5 units on the COMFORT-B (amplitude) 
from 20.00 h onward (equal to 478 min from 12.00 h) and 14.7 values on the BIS from 17.30 
h onward. In the agitated infants, no night dip (CNR) could be identified. Using the BIS as
a pharmacodynamic endpoint, the postanesthesia effect could not be described because of 
the large observed interindividual and intraindividual variability in response (Table 3). The 
effect of midazolam on the COMFORT-B was highly variable, with an interindividual coef-
ficient of variation in EC50 of 89%. Using the BIS, an estimated 57% of the infants did not 
display a significant response on midazolam (“nonresponders”). The EC50 for the subpopu-
lation “responders” was 0.63 μmol/l, with an interindividual variability of 66%. No covari-
ates, age included, could be detected. Splitting the patients in two age groups, ≥ 1 yr and < 
1 yr, according to the age for which the BIS was validated, the EC50 was 0.34 μmol/l for two 
responders in the age group ≥ 1 yr. The other eight patients did not display a response on 
the BIS. For the age group < 1 yr, 61% displayed a response on the BIS. The EC50 was 0.69 
μmol/l with an interindividual variability of 70%. 
For the influence of 1-OH-midazolam on the pharmacodynamics, an additive interaction














Figure 4 Scatter plot showing relation between age 
and elimination clearance (CL
e
) and the identifica-
tion of the genotype analysis. The two CYP3A5*1/*3 
heterozygotes are represented by squares, the two 
infants with no result for CYP3A5*3 are represented 
by diamonds. The three carriers of CYP3A7*1C 
allele are represented by gray triangles, and a black 
triangle represents the infant in which an extra 
factor was estimated. 



















































































Figure 3 Serum concentration – time observations and predictions of midazolam (A), 1-OH-midazolam (B), and 1-OH-
midazolamglucuronide (C) for a median performance after a loading dose of 1 mg, followed by a continuous infusion of 
0.5 mg/h. The solid circles represent measured midazolam and metabolite concentrations; the solid lines represent the 
individual predicted concentrations, and the dashed lines represent the population predicted concentrations.
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Table 3 Population pharmacodynamic parameter estimates of the postoperative depth of sedation using COMFORT-B 











Postoperative natural sleep pattern
agitated and nonagitated infants
BSL 10.2 (5.5) –
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78.9 (1.2) 79.0 (1.4)
PAEFF T
50,PS





1794 (44.8) 1936 (49.0) - -
Maximal score S
max
20 (19.6) 21 (25.7) - -
nonagitated infants
CNR Onset, min 478 (13.0) 356 (49.4) 330 (1.3) 345 (15.0)
Frequency, min 1430 (15.0) 1934 (41.4) 2550 (21.9) 2988 (40.8)
Amplitude,
response units















- - 99 FIXED 99 FIXED
% Responders - - 43 (40.2) 46 (41.5)
Interindividual variability, %
BSL 17 (34.3) 17 (29.2) 8 (21.9) 8 (23.6)
EC
50
89 (59.1) 77 (58.7) - -
EC
50 




, % 31 (7.2) 30 (8.0) - -
ε
2
, BIS units - - 13 (6.1) 13 (5.7)
Performance measures
-2LL 2426.7 2402.7 21915.8 21806
BIS, Bispectral index; COMFORT-B, COMFORT-Behavior score; values in parentheses are CV, coefficient of variation of the parameter
values; BSL, level of sedation at arrival; PAEFF, postanesthesia effect; T
50,PS
, time postsurgery at half maximum postanesthesia 
effect; CNR, circadian night rhythm; MEF, midazolam effect; EC
50
, midazolam concentration at half maximum effect; interindividual
variability, square root of the exponential variance of η minus 1; ε
1
, residual error proportional; ε
2




model was tested according to the Materials and Methods section. However, this model was 
unable to estimate the values of the EC50 of midazolam and 1-OH-midazolam separately. 
Further simplification of this model, assuming equal values for EC50 for both components, 
did not result in a significant decrease in objective function or interindividual variability but
only a shift of EC50 from 0.58 to 0.81 μmol/l. 
The observed and predicted depth of sedation characterized by COMFORT-B and BIS for 
a responder (A) and a nonresponder (B) and their corresponding midazolam concentra-
tions are shown in Figure 5. In Figure 6A and B, the simulated relation between time, two 
different dose regimens of midazolam, midazolam concentration, and predicted population 
response is demonstrated in terms of depth of sedation using COMFORT-B, based on the 
derived pharmacodynamic model. The influence of the covariate age on the baseline using
the COMFORT-B is shown in 6B. Figure 6C shows the postoperative natural sleep pattern 
of the nonagitated infants who did not need sedative medication. 
Figure 5 COMFORT-Behavior score (COMFORT-B; left column) and Bispectral Index (BIS; right column) versus time 
(minutes) from 12.00 h in a representative infant of the responder group (A) and the nonresponder group (B). The solid 
circles represent the observations, the solid lines represent the individual predicted depth of sedation, and the dashed 
lines represent the population predicted depth of sedation. The gray line represents the individual predicted midazolam 
concentrations
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Discussion
A population pharmacokinetic and pharmacodynamic model of midazolam and its metabo-
lites 1-OH-midazolam and 1-OH-midazolamglucuronide based on the validated COMFORT-
B scale is described to refine postoperative sedative treatment in nonventilated infants aged
3 months to 2 yr after surgery in the PICU. 
In defining the optimal dose for children, population pharmacokinetic and pharmacody-
namic modeling is useful. Key factors in this respect are that the pharmacokinetic-phar-
macodynamic correlation can be established in the clinical situation at the basis of sparse 
sampling. Furthermore, application of the population approach enables the characterization 
of interindividual variability as well as the source of this variability on the basis of covariate 
analysis. 
The pharmacokinetic model derived in this study estimated a total clearance of midazolam 
of 157 ml/min (16.7 ml · kg-1 · min-1) in nonventilated children, which is two to five times
Figure 6 Simulation of the relation between time (minutes) from 12.00 h, midazolam administration, population 
predicted midazolam concentration (dashed line), and population predicted COMFORT-Behavior score (COMFORT-B; solid 
lines). A shows the simulation of 2 mg midazolam followed by a continuous infusion of 1 mg/h in a 10-months-old infant. 
B shows the simulation of 1 mg midazolam followed by a continuous infusion of 0.5 mg/h in a 10- and a 15-month-old 
infant. C represents the natural sleep pattern of a nonagitated infant. The horizontal reference line ranges from the 






























































higher than clearance described in ventilated critically ill children or in ventilated children 
after cardiac surgery. Hughes et al.28 estimated a median clearance of 3.1 ml·kg-1·min-1 from 
steady state concentrations in critically ill infants aged 1 month to 1 yr. De Wildt3 found 
a mean clearance of 5.0 ml·kg-1·min-1 in intensive care patients aged 2 days to 17 yr. In 
addition, they found a 2.5 times lower ratio for 1-OH-midazolam/midazolam concentrations. 
Mathews et al.29 reported a clearance of 9.6 ml·kg-1·min-1in children aged 2-8 yr as continu-
ous infusion after cardiac surgery. Compared with nonventilated children aged 6 months 
to 2 yr after a single dose before minor in-hospital or day-stay procedures, the clearance 
found in our population was slightly higher (16.7 ml · kg-1 · min-1 vs. 11.3 ml · kg-1 · min-1)5 
but was comparable to clearance described in nonventilated healthy adults after a bolus 
injection (16.1 ml · kg-1 · min-1).30 Our pharmacokinetic analysis demonstrates that nonven-
tilated infants after major surgery may require relatively high doses of midazolam. Because 
midazolam is an intermediate extraction ratio drug, this may be attributable to the relatively 
healthy state of the children and to the absence of mechanical ventilation, which affects the 
hepatic blood flow.
A high degree of interindividual variability in clearance (coefficient of variation, 54%) was
seen, which could not be attributed to body weight, venous or arterial sampling, frequen-
cies of CYP3A4, 5 or 7 variant alleles, or hemodynamic parameters, probably because of 
the narrow variability in patient characteristics and condition. The clearance tended to be 
related to age, but the relatively small number of infants older than 15 months may be the 
cause that the trend did not reach statistical significance. As a consequence, dose recom-
mendations may be less appropriate for infants aged 15-24 months. Regarding arterial and 
venous sampling, there is evidence that differences are only relevant during the rapid distri-
bution phase,31 and this does not seems to be of clinical relevance when midazolam is used 
as continuous infusion in sedated children. In one heterozygous CYP3A7*1C infant who 
needed high doses of midazolam, the incorporation in the model of a multiplication factor 
of CL1 and CL3 resulted in a significantly better fit, which means that the oxidation and
glucuronidation was between two and three times faster than in the other infants. The allele 
CYP3A7*1C is associated with continued high hepatic and intestinal CYP3A7 expression.32 
The clinical relevance of the finding is yet unclear because it is limited by the frequency of
the alleles as relates to the number of patients because it has been analyzed as part of a large 
DNA data study. Large studies may answer the question of whether this investigated allele 
plays a significant role.
Depth of sedation may be difficult to assess in children. The COMFORT scale is validated
in the PICU and measures six behavioral items as well as two physiological items (mean 
arterial pressure and heart rate).33 Because the physiological items are controlled in the 
intensive care unit, the COMFORT-B score was developed in Canada by Carnevale and 
Razack15 and is routinely used in most PICUs in The Netherlands.14 The BIS is a processed 
electroencephalographic parameter developed using adult data and is objective and easy to 
use, but is not yet validated for children below the age of 1 yr. The impact of age on the BIS 
is still debated, with divergent findings.34,17 
Using the COMFORT-B as pharmacodynamic endpoint, depth of sedation was described 
75
Pharmacokinetics and effect of midazolam in infants
as a function of a baseline, a postanesthesia effect, a CNR, and the midazolam effect. Age 
was found to be a significant covariate for the baseline (the state of comfort at arrival) in the
PSICU. This indicates that young children may be more sensitive to the environment and 
emotional distress than older infants. Non-agitated children displayed on the COMFORT-
B a night dip starting at 20.00 h and a slower washout period of the postanesthesia effect 
(1794 vs. 537 min, respectively) compared with agitated infants. In agitated children, no 
night dip was observed. In these infants, the midazolam effect was implemented using an 
Emax model. Using the BIS, a large residual error and a large interindividual variability were 
found, resulting in the inability to detect the postanesthesia effect. This confirms the clinical
observation that the BIS highly fluctuates in particular in lightly sedated children. This may
be explained by the fact that light sedation may be influenced more by the environment.35 
Fifty-six percent of the infants did not show a response of midazolam on the BIS, whereas 
midazolam influenced the COMFORT-B in all infants, although the interindividual vari-
ability in EC50 was large (89%) and no patient characteristics (covariates) could increase the 
predictability. Taking into account the age for which the BIS is validated, 8 of the 10 patients 
≥ 1 yr did not show a response of midazolam on the BIS. Therefore, the BIS seems less 
sensitive and less specific for the effect of midazolam than the COMFORT-B score.
In this study, no separate EC50 could be identified for midazolam parent and metabolite,
because the concentration profiles ran parallel in time while the concentration of the metabo-
lite 1-OH-midazolam was low throughout the entire treatment period (ratio 1-OH-midazolam/
midazolam is 0.37). Therefore, the observed effect was only ascribed to midazolam, using a 
simple Emax model. Sampling immediately after the bolus may have provided a different ratio 
of metabolite and parent drug, which would enable identification of contribution of 1-OH-
midazolam to the effect. It has been shown before in a study after oral or separate intravenous 
administration that 1-OH-midazolam has pharmacological activity.4,12 However, after intra-
venous administration, the concentration of the metabolite is relatively low compared with 
oral use. Also in adults after coronary artery bypass grafting, no effect of 1-OH-midazolam 
could be detected,36 whereas 1-OH-midazolam levels were above 10 μg/l in only 11% of the 
patients and the ratio was at most 0.20.37
Currently, no population pharmacodynamic studies in adults are available for comparison 
of the sensitivity of infants to adults using these sedation scales. In adults, the Ramsay 
score is often used to assess the level of sedation. Using the Ramsay scale, the midazolam 
concentrations in adults associated with 50% probability of a level of sedation 2 (coopera-
tive), 3 (drowsy or asleep, easily responded to commands), and 4 (asleep, brisk response 
to a glabellar tap) were 0.017, 0.22, and 0.52 μmol/l, respectively.36 In the present study, 
after a bolus of 1 mg and a continuous infusion of 0.5 mg/h, the predicted concentration in 
the infants is 0.16 μmol/l, corresponding to values between 12 and 14 on the COMFORT-B 
(lightly sedated). Although comparison is difficult, it seems that the midazolam concentra-
tion to achieve light sedation in infants is comparable to that in adults.
In a previous article, we described a pharmacokinetic and pharmacodynamic model for 
propofol in this population group19 and discussed the safety of propofol compared with 
midazolam.18 As found for midazolam, clearance of propofol was also higher than the values 
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reported in the literature. The results of the current analysis demonstrate that midazolam 
shows a less predictable effect than propofol, because the interindividual variability in 
EC50 (89% vs. 47%) on the COMFORT-B is higher, whereas the residual (intraindividual) 
variability and elimination half-life are comparable (30% vs. 32% and 16.8 vs. 18.6 min, 
respectively). The results indicate that propofol may be preferred over midazolam as a 
sedative in intensive care, which should be further studied taking into account the safety 
recommendations.
The pharmacokinetic and pharmacodynamic population model shows that a loading dose of 
1 mg followed by a continuous infusion of 0.5 mg/h midazolam is the optimal initial dose 
for a desired COMFORT-B score of 12-14 during the first night after major surgery in non-
ventilated infants aged 1 yr. Because of large interindividual variability, further individual 
titration is important for midazolam. Although no significant effect of age on the clearance
could be detected, the initial dose recommendation may be less suitable for application in 
infants older than 15 months.
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Sedation guidelines and clinical practice
Abstract
Background: Sedation protocols in the intensive care have been shown to reduce the duration 
of mechanical ventilation and length of stay. In this study a sedation protocol for long-term 
sedated patients is implemented and evaluated by comparing target levels to observed levels 
of sedation.
Methods: Propofol administration was titrated by the nurses to a physician determined 
Ramsay score, using a protocol driven approach. Twenty-six critically ill patients were 
included, who were expected to require mechanical ventilation and sedation > 2 days. The 
BIS was recorded concurrently.
Results: 541 Ramsay observations were obtained with a median of 16 observations per 
patient. Target Ramsay scores were achieved in only 28% of the assessments (difference d 
between observed and target equals 0), while 35% were within clinical acceptable differences 
(d = -1 or d = +1) and 33% were recorded as oversedated (d > 1). The mean difference d 
was +0.93 (SD 1.3) and represented the consistent significantly (P < 0.001) deeper level 
of sedation titrated by the nurses than target by the physicians. When target scores were 
achieved, a dose reduction was attempted 15% of the time. At oversedation (d > 1) the 
infusion rate was mostly maintained (63%). Mean BIS values were significantly different
between the groups agitation, light and deep sedation (P < 0.001). The Ramsay score and the 
BIS were moderately (r = -0.570, P < 0.01) correlated.
Conclusion: We found that in clinical practice, critically ill patients tend to be oversedated. 
Repeated feedback may be necessary in order to benefit from claimed advantages of a
sedation protocol.
Introduction
Mechanically ventilated patients require an appropriate level of sedation and should not 
have excessive levels to reduce the risk of prolonged mechanical ventilation, related compli-
cations and length of stay in the intensive care unit (ICU). A nurse-driven sedation protocol1 
and daily interruption of sedation2 can decrease these risks, which resulted in recommenda-
tion of the Society of Critical Care Medicine3 to use sedation guidelines. However, there 
is considerable variability between published evidence and local guidelines with regard to 
the choice of sedative, sedation scoring systems and the practice of daily interruption.4 In 
addition, although most ICUs have developed and stated a (local) sedation protocol, actual 
clinical practice may (wittingly or unwittingly) differ significantly and this may affect
the intended improved health outcome.5 Specifically, deeper levels of sedation used to be
common in most ICUs before the introduction of sedation protocols. Surprisingly, little 
research is published on the adherence to sedation protocols in the ICU, especially for long 
term sedated critically ill patients who may benefit the most from the claimed advantages.
In this study we implemented a sedation protocol for critically ill patients who were expected 
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to be mechanically ventilated and sedated for more than 2 days. We evaluated the com-
pliance to the target levels of sedation. Assessment of sedation was performed using the 
Ramsay score. The Bispectral index (BIS) was recorded concurrently, thereby exploring the 
BIS as an additional instrument to measure the level of sedation. This enables examination 
of the relation between the Ramsay and the BIS as a secondary objective, as BIS use is not 
yet clear in the ICU.6
Materials and Methods
The study was performed in a 30 bed mixed surgical/medical intensive care unit at the St 
Antonius Hospital in Nieuwegein, The Netherlands, a tertiary teaching hospital. Patients 
were eligible for participation in the study if they were between ages of 20-90 years and 
expected to be mechanically ventilated and sedated for more than 2 days with propofol as 
the primary sedative choice. Patients with known hypertriglyceridemia, allergic history to 
propofol or pregnancy were excluded as were patients with a known history of drug abuse. 
The study was approved by the Ethics Committee of the St Antonius Hospital, Nieuwegein, 
The Netherlands. Written informed consent was obtained from the next of kin.
Development of guideline
Two anesthesiologist-intensivists, two hospital pharmacists and seven ICU nurses developed 
the sedation guideline for propofol. Propofol was chosen as the drug of choice for long-
term sedation, because of the high level of experience with propofol in our clinic, the short 
duration of action which enables rapid awakening and the local availability of Propofol 
6% preventing high fat loads upon prolonged use. Before this study, the nursing staff was 
familiar with the Ramsay score, but levels of sedation were not systematically scored and 
recorded.7 At the time of the investigation, the BIS had not been introduced to monitor 
sedation in the ICU, despite its routine use in anaesthesia. One ICU nurse tested the feasi-
bility of daily wake up and assessment of the sedation level by the nurses in a pilot study 
during a period of 1.5 months. Eventually, the final guideline (Figure 1) was presented to 
and discussed with the physicians and nurses and distributed to the physicians by internal 
post. At inclusion of each patient, the guideline and disadvantages of inappropriately deep 
sedation were again discussed with the nurses in the morning and in the afternoon, reaching 
2 of the 3 shifts of the primary care nurses daily. Nurses were asked to list reasons for dose 
adjustments and comment on the patients’ sedation state on the Case Report Form. The 
nursing staff was instructed to titrate on the Ramsay as shown in the guideline and warned 
not to use BIS values because of lack of validation. They were told that the BIS decreases 
with level of consciousness during anaesthesia, but that the role and target values of the BIS 
in the intensive care patients (without muscle relaxants) are not clear.
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Figure 1 Schematic representation of the sedation protocol.
The Bispectral index was monitored continuously.


























Sedative and analgesic regimen
Propofol sedation (Propofol 6% 7,8 or Propofol 1% (AstraZeneca, Zoetermeer, The Netherlands) 
was guided by a sedation protocol (Figure 1), in which the attending physician determined 
twice daily the target Ramsay score, the need of interruption of propofol or the definitive
discontinuation of the sedative. The Ramsay score9 is a six point scale: 1) patient anxious, 
agitated, restless, 2) cooperative, orientated and tranquil, 3) drowsy or asleep, easily re-
sponding to commands, 4) patient asleep, brisk response to a light glabellar tap, 5) patient 
asleep, sluggish response to a light glabellar tap and 6) patient asleep, no response to a light 
glabellar tap. The primary care nurse adjusted the infusion rates according to the target 
Ramsay score and assessed in standard manner 4 times daily the level of sedation and 30 
and 60 minutes after dose adjustment. If the target Ramsay score was achieved, a decrease in 
dose rate of approximately 10% was attempted. If patients were agitated, the Numeric Rating 
Scale (a 0-10 point scale) was used as pain instrument to determine whether analgesia was 
well controlled (NRS ≤ 4) before the propofol infusion rate was increased. Higher require-
ments than a maximum propofol infusion rate of 6 mg · kg-1 · h-1 for a maximum of 6 h were 
considered therapeutic failures.
The BIS was recorded continuous concurrently as an objective marker for the depth of 
sedatives (BIS® XP, A 2000 revision 3.22, Aspect Medical Systems) using the quarto BIS® 




Gender, M/F 16 / 10
Age, years 70 (38-81)
Weight, kg 77.5 (50-120)
APACHE score at admission ICU 21 (12-49)
SOFA score at inclusion 12 (5-21)
Diagnostic group 26
   Cardiac (surgical/medical) 4 / 3
   (ruptured) (thoraco) abdominal aortic aneurysm 5
   sepsis 6
   pneumonia 4
   miscellaneous a 4
Propofol infusion duration at inclusion, days 1.5 (0-12)
Studied propofol infusion duration, days 1.9 (0.7-9.7)
Propofol infusion rate, mg/h 147 (51-398)
Propofol infusion rate, mg·kg-1·h-1 2.0 (0.4-5.3)
Number of infusion rate adjustments per patient per day
   increases 1.1 (0-6.1)
   decreases 1.1 (0-7.1)
Morphine infusion rate, mg/h 0.8 (0-3)
a: gastric tube reconstruction, femoropopliteal bypass surgery, hyperthermic intra-peritoneal chemotherapy, necrotizing 
pancreatitis.
 Table 1 Patient characteristics (n=26). Data are numbers and median (minimum-maximum).
Measurements
The Acute Physiology and Chronic Health Evaluation (APACHE II) score10 was determined 
on the first 24 h at admission to the ICU. The severity of illness was measured by the Se-
quential Organ Failure Assessment (SOFA) score.11 For safety purposes serum triglycerides 
were monitored.
Statistical analysis 
Statistical analysis was performed using SPSS (version 12.01 for windows; SPSS, Chicago, 
IL, USA). Measurement of agreement between the target Ramsay score and the observed 
Ramsay score was performed using a Bland Altman plot.12,13 The Wilcoxon signed ranks test 
for paired data was used to test the null hypothesis that the observed Ramsay score equalled 
the target Ramsay score.
To study the relation between the Ramsay and the BIS, four paired observations were 
randomly obtained per patient. The Spearman’s rho was used to determine the correlation 
between paired Bispectral index and Ramsay scores. The Kruskal Wallis test was used to 
determine whether the mean BIS values differed between the Ramsay groups agitation 
(Ramsay 1), light sedation (Ramsay 2-4) and deep sedation (Ramsay 5-6).
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Figure 2 Bland-Altman plot of the differences between observed and target Ramsay score. The horizontal solid line 
represents the mean of the differences between the observed and the target Ramsay score. The horizontal dashed lines 
represent the limits of agreement at ±1.96SD.


































The characteristics of the patients participating in the study are shown in Table 1. The studied 
population included 12 surgical and 14 medical patients. Patients were studied for 0.7-9.5 
days (median 1.9 days).
Evaluation of the stated sedation protocol
A total of 541 Ramsay observations were obtained with a median of 16 observations (4-67) 
per patient. In 15% of the observations a period of deep sedation (Ramsay 5 and 6) was 
desired according to the physicians, because of pressure - and volume controlled ventila-
tion, prone position, defibrillation and/or severe critical illness (SOFA > 15). Light sedation
(Ramsay 2-4) was desirable in 67%. In 17% (96 missing values), the target Ramsay score 
was not recorded. As a measure of agreement between the target Ramsay score and the 
observed Ramsay score, a Bland-Altman plot was constructed (Figure 2). In this plot, the 
mean difference between the observed and target Ramsay score (d) is + 0.93 (SD 1.3) and 
represents a consistently deeper level of sedation titrated by the nurses than target by the 
physicians. Thirty-five percent of the assessments were within clinical acceptable differ-
ences (d = -1 or d = 1). Thirty-three percent could be recorded as oversedated (d > 1). The 
observed deeper level of sedation was significantly different (P < 0.001). As the period of 
sedation and thus the number of assessments varied, pairs of means were also calculated 
from the mean of each patient. A comparable mean difference of + 0.96 (SD 1.4) Ramsay 
score was calculated and percentages of clinical acceptability and oversedation were com-
parable. In fourteen patients the difference between Ramsay observed and target was signifi-
cantly different (P < 0.05) (all deeper). Nurses titrated in 62% to a deep sedation level of 5 
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and 6. Dose titrations occurred at all levels of sedation. At close titration (d = -1, n=27 and 
+1, n=118), the dose was increased and decreased within 3 hours by the nurses in both 19% 
of the assessments. At failure d < -1 (n=14) and d > 1 (n=128) the infusion was increased 
and decreased in 71% and 28%, respectively. At correct titration (n=112) a dose reduction 
was attempted in only 15% of all assessments. The assessments during interruption were 
excluded from this analysis (46 values). As reported in Table 1, infusion rates were adjusted 
on average 2.2 times per patient per day. Nurses reported the following reasons for lack 
of downwards titration in patients who were deeper sedated than target: motor agitation, 
nursing care, change in mechanical ventilation, hemodynamic effects of propofol, severity 
of illness, lack of time and difficulty in titration. Interruption was desired by the physician
in 9 patients (35%), which were all postoperative patients who were at risk for neurological 
complications while undergoing pressure control ventilation. The median duration of inter-
ruption was 32 minutes (15-238, n=12). After restarting, in 33 percent the infusion rates 
could be decreased to 50% of the previous rate. In one patient, interruption after 44 hours 
infusion lead to agitation, manifested as extreme hypertension. In one patient there was no 
need to restart the sedative after the interruption, resulting in successful extubation.
Two patients showed high dose requirements of propofol and cholestasis, being therapeutic 
failures and sedation was continued with midazolam.
Exploration of the role of the Bispectral Index:
A total of 104 paired observations were analyzed. Mean BIS values were significantly
different between the groups agitation, light sedation and deep sedation (P < 0.001) (Table 2). 
BIS values less than 60, usually associated with deep sedation14 were recorded in 78% of 
the oversedated patients (d ≥ 2 Ramsay scores). There was a moderate, but statistically 
significant correlation between Ramsay and BIS (Spearman’s rho = -0.570, P < 0.01). One 
critically ill patient showed during 3.7 days continuously a high BIS and electromyographic 
activity (EMG), while the level of sedation was clinically assessed at Ramsay 4-6. After 
administration of muscle relaxant (bolus dose of 50 mg rocuronium) for facilitation of endo-
tracheal tube exchange, the BIS and EMG markedly decreased from 94 ± 3.6 to a minimum 
of 29 and 53 ± 3.2 dB to 26 dB, respectively.
Ramsay BIS mean N SD
1  (agitation) 93 4 2.20
2-4  (light sedation) 75 37 22.0
5-6  (deep sedation) 55 63 20.0
Total 104
Table 2 Mean Bispectral Index values for the grouped Ramsay sedation scores.
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Discussion
In this study we show that actual clinical sedation practice often differs from sedation guide-
lines, evidenced by differences between the target and actually observed levels of sedation 
in long-term sedated critically ill patients. The intention of sedation guidelines to improve 
the patients’ outcome by reduction of the duration of the mechanical ventilation, ICU and 
hospital length of stay1,2 may therefore be not fully identified in current practice.
According to the advice of the Committee of the Society of Critical Care Medicine3 and the 
Netherlands Society of Intensive Care, doses of the sedative were adjusted to the Ramsay 
scale using a protocol-driven approach, a situation similar to most ICUs. However, we 
found that patients were often sedated to a deeper level (P < 0.001) than was defined by the
attending physician (Figure 2). Specifically, the differences between the observed and target
Ramsay score (d) was +0.93 (SD 1.3) Ramsay score. Deep levels of sedation Ramsay 5 and 
6 were scored by the nurses in 62% in total, whereas deep sedation was defined as ideal by
the physician in only 15% of the cases.
The defined deep sedation by the physicians seems judged to the mode of mechanical ventila-
tion, although definitions of ideal sedation in critically ill patients may be disputable. Previous
publications have stated different Ramsay scores as ideal varying from Ramsay 3-415, 5-616, 
2-3 to deep sedation for patients nursed with unconventional ventilator strategies (prone 
positioning, pressure controlled ventilation and low tidal volumes).17 According to the 
nurses’ opinion in our ICU, some patients required deeper sedation because of severe illness, 
motor agitation, facilitation of caring practices and variation of mode of ventilation during 
the day. The rate of infusion was often increased at undersedation, however, oversedation 
was not reliable followed by a decrease in infusion rate, which suggest that ICU nurses are 
particularly focused on reducing patient distress. Reported barriers to titrate correctly were 
lack of time, difficulty to titrate and concern on the hypotensive effects of propofol. However, 
the low median numbers of propofol adjustments per day indicate a tendency to keep the 
same infusion rate constant. Interestingly, Cabana et al.18 offered reasons why physicians do 
not follow practice guidelines. For physicians, lack of familiarity and awareness affecting 
knowledge, lack of agreement affecting attitude and finally external barriers as lack of time
affecting attitude were the most often reported reasons for limiting adherence. The present 
study suggests that for ICU nurses, lack of familiarity or awareness are not the exclusive 
reasons for low adherence and inappropriately deep sedation, as the nurses were instructed 
and special emphasis was put on the negative effects of oversedation. Similar results were 
shown in a previous study.5 Unfortunately, comments on non-compliance were not exten-
sively reported by the nurses in this study. Further studies are therefore needed to find the
exact reasons of the nurses for not following guidelines in practice. In our view, potential 
quality improvement of guideline adherence may include frequent redefinition of the target
levels in critically ill patients, since their condition may change rapidly during the day. 
Moreover, daily reevaluation of the achieved sedation level in the multidisciplinary meeting 
to allow for feedback from the primary care nurse.
Although patients were sedated to a deeper level than target, knowledge of the effects of 
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oversedation may have already resulted in our ICU in a less aggressive sedation level. In a 
previous study from our group in 1999/2000,8 we noted a tendency to aggressively sedate 
critically ill patients during the whole ICU period, assessing 60-80% of the sedation levels at 
Ramsay 6 without sedation protocol, judged as adequate by the nurses, while in the current 
study 34% of the assessments were in Ramsay 6 at comparable severity of illness.
In contrast to the defined daily interruption in the studied protocol, interruption for neuro-
logical assessment was only standard practice in patients who were at risk for neurologi-
cal complications following vascular surgery. Daily interruption was not primarily used to 
optimize the dosage or decrease the tendency to keep the same infusion rate, using lower 
infusion rates at restarting. However, if sedatives are well titrated a wake-up period will not 
be required theoretically and the benefit for sedatives with low risk of accumulation may be
less pronounced.2
To evaluate the BIS as an objective endpoint of a patient’s level of sedation, the BIS was 
monitored continuously in addition to the Ramsay score. Although the Ramsay score is the 
most widely used titration endpoint, it is well known that the Ramsay score is not ideal as 
sedation instrument. Due to the subjective nature of the score, it is for example difficult
to discriminate between 3, 4 and 5,19 while Ramsay 6 seems to be a mixture of different 
levels of unconsciousness.20 In our study, BIS values were found to be significantly different
between agitation, light sedation and deep sedation with values of 93, 75 and 55, respec-
tively. Between the scales, a moderately significant correlation (r=-0.570) was found. In the
oversedated patients (d ≥ 2 Ramsay score) low BIS values less than 60, associated with deep 
sedation14 were recorded in 78% of the critical ill patients. Apart from the shortcomings of 
the BIS, such as EMG interference,21 the BIS in our view might be helpful to differentiate 
in level of sedation in deeply sedated patients and might stimulate nurses to decrease the 
infusion rate if low values of the BIS are recorded, which should be evaluated in further 
studies.
In conclusion, in order to benefit from claimed advantages of a sedation protocol in the ICU,
its implementation should be accompanied with repeated feedback, since in clinical practice 
in 33% of the cases, patients were sedated to a deeper level by the nurses than was defined
by the attending physician.
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Disease severity and propofol effect
Abstract
Objective: As oversedation is still common and significant variability between and within
critically ill patients makes empiric dosing difficult, the population pharmacokinetics and 
pharmacodynamics of propofol upon long-term use are characterized, particularly focused 
on the varying disease state as determinant of the effect.
Methods: Twenty-six critically ill patients were evaluated during 0.7-9.5 days (median 
1.9 days) using the Ramsay scale and the Bispectral index as pharmacodynamic endpoints. 
NONMEM V was applied for population pharmacokinetic and pharmacodynamic 
modeling.
Results: Propofol pharmacokinetics was described by a two-compartment model, in which 
cardiac patients had a 38% lower clearance. Severity of illness, expressed as a Sequential 
Organ Failure Assessment (SOFA) score, particularly influenced the pharmacodynamics and
to a minor degree the pharmacokinetics. Deeper levels of sedation were found with an in-
creasing SOFA score.
Conclusion: With severe illness, critically ill patients will need downward titration of 
propofol. In patients with cardiac failure, the propofol dosages should be reduced by 38%.
Introduction
Owing to its short duration of action, propofol is considered the preferred sedative in criti-
cally ill intensive care patients when rapid awakening is important, wheras lorazepam may 
be considered for sedation of more than 3 days.1 Because of its ease of titration, its safety in 
patients with renal and hepatic disease, and the possibility of rapid awakening, propofol also 
appears to be very suitable for long-term sedation. However, the association of long-term 
use (> 48 h) and unlicensed high doses (> 4 mg · kg-1 · h-1) with propofol infusion syndrome2 
limits its use for long-term sedation. Additionally, independent of the choice of the sedative, 
oversedation remains a great problem, prolonging the duration of ventilation and the stay 
in the intensive care unit (ICU). This has led to the development of nursing-implemented 
sedation protocols and daily sedative interruption.3,4 However, significant variability, not
only between patients but also within individual patients, makes the empiric dosing of 
propofol difficult. To optimize propofol dosing for long-term use, pharmacokinetics and
pharmacodynamics of propofol in critically ill patients are investigated during their stay in 
the ICU. A specific objective was to investigate the influence of the changing condition of




The study was approved by the local Ethics Committee of the St Antonius Hospital, Nieuwe-
gein, The Netherlands. Written informed consent was obtained from the relatives. Inclusion 
criteria included patients between 20-90 years who were expected to be mechanically ven-
tilated and sedated with propofol for more than 2 days. Exclusion criteria included hypertri-
glyceridemia, allergic history to propofol, pregnancy, or a known history of drug abuse.
Sedative and analgesic regimen
Propofol doses were adjusted to the Ramsay sedation scale using a protocol-driven approach. 
The attending physician determined twice daily the target Ramsay score, the need for in-
terruption of propofol, or the definitive discontinuation of the sedative. The Ramsay scale 
distinguishes six levels of sedation5: (1) anxious, agitated, restless; (2) cooperative, orien-
tated and tranquil; (3) drowsy or asleep, easily responding to commands; (4) asleep, brisk 
response to a light glabellar tap; (5) asleep, sluggish response to a light glabellar tap; and 
(6) asleep, no response to a light glabellar tap. The primary care nurse adjusted the infusion 
rates according to the target Ramsay score and assessed in standard manner four times daily 
the level of sedation. If patients were oversedated or undersedated, a dose adjustment of 
25% was recommended. At agitation, the Numeric Rating Scale (a 0-10 point scale) was 
used as pain instrument to determine whether analgesia was well controlled (NRS ≤ 4) 
before the propofol infusion rate was increased. The efficacy was determined 30 and 60 min
after dose adjustment. If the target Ramsay score was achieved, a decrease in dose rate of 
approximately 10% was attempted. At interruption, the recommended restarting infusion 
rate was 50% of the previous dose. The BIS was monitored continuously and the values 
were noted at 15 min intervals by the investigator (BIS® XP, A-2000 revision 3.22, Aspect 
Medical Systems) using the quatro BIS® XP sensor electrodes. The values of BIS range 
from 100 (awake) to 0 (isoelectric electroencephalogram). Each day, the nursing staff was 
instructed not to use BIS values because of lack of validation. Heart rate, blood pressure, 
central venous pressure, temperature, and saturation were monitored continuously. Clinical 
laboratory tests were routinely monitored. For safety purposes, serum triglycerides were 
monitored two times daily. The SOFA score was computed daily to evaluate the time course 
of the severity of illness and was based on the degree of organ dysfunction. For each organ 
system (respiration, coagulation, liver, cardiovascular, central nervous system, and renal), 
the worst value ranging from 0 to 4 in each 24-h period was considered, resulting in a total 
score of 0-24.6
Blood sampling and analysis
Arterial blood samples (2 ml) were collected in oxalate tubes four times daily at 3.00, 7.00, 
15.00 and 21.00 h and 30, and 60 minutes after each dose adjustment. After discontinuation 
of the propofol infusion, samples were taken at 30 and 60 minutes intervals after stopping up 
to the closest daily collection time. The samples were stored at 4ºC. Propofol concentrations 
were measured by high-performance liquid chromatography with fluorescence detection.7 
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The limit of quantification was 0.035 mg/l. Inter- and intra-assay coefficients of variation
were less than 9.6 and 2.6%, respectively, over the concentration range 0.5-5 mg/l.
Data analysis
The analysis was performed using NONMEM (Non-Linear Mixed effect Modeling) 
(GloboMax LLC, Hanover, MD, version V release 1.1)8 by use of the first-order conditional
estimation (Method 1) with η-ε interaction. S-plus (Insightful software, Seattle, WA, version 
6.2) was used to visualize the data. Population pharmacokinetic and pharmacodynamic data 
were sequentially analyzed. Discrimination between different models was made by compari-
son of the objective function. A value of P < 0.005, representing a decrease of 7.8 points in 
the objective function, was considered statistically significant. In addition, goodness-of-fit
plots, including observations vs. individual predictions, observations vs. population predic-
tions, weighted residuals vs. time and population predictions vs. weighted residuals were 
used for diagnostic purposes of both pharmacokinetic and pharmacodynamic data. Further-
more, the confidence interval of the parameter estimates, the correlation matrix and visual
improvement of the individual plots were used to evaluate the model.
Pharmacokinetic model
Propofol pharmacokinetics were adequately described by a two-compartment model 
(ADVAN3 TRANS4), parameterized in terms of volume of the central compartment (V1), 
volume of the peripheral compartment (V2), the intercompartmental clearance (Q), and 
clearance (CL). The individual value (post hoc value) of the parameters of the ith subject 
was modeled by
(1)
where θmean is the population mean and ηi is assumed to be a random variable with zero mean 
and variance ω2. The residual error was best described with a proportional error model. This 
means for the jth observed concentration of the ith individual the relation
(2)
where cpred is predicted propofol concentration and εij a random variable with mean zero and 
variance σ2.
Pharmacodynamic model using the Ramsay score as endpoint
The Ramsay sedation scores were described using a proportional odds model for the prob-
ability (π) of observing a particular Ramsay (RSi) sedation level.





θ1-5 describes the sedation level without propofol and θ6 describes the magnitude of the 
propofol effect. η is a normally distributed, zero mean random variable with standard 
deviation ω describing interindividual variability.
The corresponding probabilities (π) are given by:
(4)
(5)
For diagnostic purposes “naïve pooled observed” probabilities were defined as described
by Knibbe et al.10 and Somma et al.11. In brief, the available propofol individual predicted 
data and corresponding Ramsay sedation scores were rank-ordered, independent of the indi-
vidual from whom the data were obtained (naïve pooled). For each concentration and its four 
closest lower and four closest higher concentrations, the cumulative probability for each of 
the Ramsay sedation score was calculated (fraction of 9). The naïve pooled observed prob-
abilities were plotted vs. the concentrations and then compared with the predicted probabili-
ties of the population model. The percentage of correct predictions (the actually observed 
sedation score equals predicted sedation score) and close predictions (the actually observed 
sedation score equals the predicted sedation score ± 1) were computed.
Pharmacodynamic model using the BIS as endpoint
The BIS data were described by a sigmoidal Emax model, which was directly linked to the 
propofol concentration in the central compartment.
(6)
where BIS0 is the baseline BIS value, which is equal to 100 (fully awake); Emax,i is the 
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maximum possible effect of propofol on the BIS, which is assumed to be 100 in the ith 
subject; C1,ij is the individual predicted propofol concentration at the central volume; γ is 
the steepness of the concentration vs. response relation; and EC50 is the propofol concentra-
tion (mg/l) at half the maximum score. Pharmacodynamic parameters were assumed to be 
log-normally distributed. The interindividual variable (ηi) was assumed to be symmetrically 
distributed with mean zero and variance ω2. One critically ill patient was excluded from 
the population estimate for EC50 as the electromyographic activity (continuously > 42 dB, 
median 51 dB) was considered to artifactually increase the BIS values.12 The residual error 
was best characterized by a proportional error model.
(7)
where Yij represents the observed BIS effect in the ith subject at the jth time point.
Covariate analysis
The time-independent covariates body weight, age, body mass index, gender, and diagnos-
tic group (e.g. cardiac failure) were plotted subsequently against the individual post-hoc 
parameter estimates and the weighted residuals to visualize potential relationships. Time-
dependent covariates, such as duration of propofol administration and SOFA score, and the 
time-independent covariates were tested for statistical significance by formal inclusion of
covariate effects in the model, followed by evaluation of the minimum value of the objective 
function and confidence intervals of the parameters. The pharmacokinetic parameters were
also tested for correlation with heart rate, mean arterial blood pressure, continuous venove-
nous haemofiltration, temperature, triglycerides, positive end expiratory pressure, dopamine,
norepinephrine, morphine dose and  formulation. The pharmacodynamic parameters were 
additionally tested for correlation with urea concentration. Starting from the basic model 
without covariates, the covariate model was first built up using forward inclusion. The con-
tribution of each covariate was confirmed by stepwise backward deletion. In the final model
all covariates associated with a significant increase in objective function after elimination
were maintained. The choice of the model was further evaluated as described in the data 
analysis.
Validation
The developed population pharmacokinetic and pharmacodynamic model using the Ramsay 
scale was externally validated by Knibbe et al.,10 against data of the critically ill patients 
who had similar characteristics as the current population and who were studied in the same 
hospital. The pharmacodynamic model characterizing the BIS was internally validated by 




Patients’ characteristics are shown in Table 1.
Pharmacokinetics
The pharmacokinetic model was based on 494 samples from 26 critically ill patients (a 
median of 15 (3-54) propofol concentrations). A two-compartment pharmacokinetic model 
using cardiac failure and SOFA score as a covariate of clearance and peripheral volume, 
respectively, best described the observations. The clearance in critically ill patients 
recovering from complicated cardiac bypass surgery (rethoracotomy or need of inotropics) 
or heart failure (indicated as the cardiac failure group) was 62% that of critically ill patients 
without heart failure (-2LL decreased from -879.7 to -895.9). The peripheral volume (V2) 
increased linearly with the improving condition of the patients expressed as SOFA score, 
as shown by a significant reduction in the -2LL from -879.7 to -888.9. No other covariates
tested were found to improve the fit or to account for part of the observed interindividual
variability. Table 2 shows the pharmacokinetic parameter values along with their confidence
intervals and the interindividual variability of the basic model without covariates and the 
final model. The diagnostics and the concentration-time observations and individual predic-
tions of the final model are shown in Figure 1 A-E. External validation of the final model
against the data of Knibbe et al.,10 demonstrated the robustness of the current model (Figure 
1F). Evaluation of the basic model without covariates resulted in an overestimation of the 
concentrations over the total range, which demonstrates that the covariates are also of value 
in the external population.
On the basis of simulations from the final pharmacokinetic model, propofol concentrations
Gender, M/F 16 / 10
Age, years 70 (38-81)
Weight, kg 77.5 (50-120)
APACHE score at admission ICU 21 (12-49)
SOFA score at inclusion 12 (5-21)
Diagnostic group
   Cardiac (surgical/medical)
   (ruptured) (thoraco) abdominal aortic aneurysm
   sepsis
   pneumonia







Propofol infusion duration at inclusion, days
Studied propofol infusion duration, days
1.5 (0-12)
1.9 (0.7-9.7)
Propofol infusion rate (mg/min)
Propofol infusion rate (mg·kg-1·h-1)
2.45 (0.8-6.6)
2.0 (0.4-5.3)
Table 1 Patient characteristics (n=26). Data are median (minimum-maximum).
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Figure 1 
Diagnostic plots, including (A) observations vs. individual predicted propofol concentrations , (B) observations vs. 
population predictions, (C) weighted residuals vs. time , and (D) weighted residuals vs. population predictions by the 
final model, superimposed on the line x=y (line of identity) and the trend line (broken black line). (E) Individual pre-
dictions (lines) and observations (numbers) vs. time. (F) Diagnostic plot of the external validation data set, including 
measured propofol concentrations vs. predicted concentrations by the final model, superimposed on the line x=y (line
of identity) and the loess smooth line (broken black line). The broken gray line shows the loess smooth line predicted 
by the basic model without covariates. The numbers represent the different critically ill patients.
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Figure 2 Simulated propofol concentration vs. time relationship in critically ill patients with different cardiac function
(cardiac failure, solid gray line; noncardiac failure, solid black line), who receive a continuous infusion of 2.5 mg/min 
propofol and show varying severity of disease (SOFA 3, --·; SOFA 9, solid black line; SOFA 15, dashed line).





















Table 2 Population parameter estimates of the basic pharmacokinetic (PK) model and the final model with cardiac
failure and SOFA score as covariates.
Parameter Basic PK model Mean (CV%) Final PK model Mean (CV%)
Fixed effects
CL, l/min






, l 17.2 (37.1) 19.9 (28.8)
V
2
, l 956 (19.3) 1140 (19.3) – 55.4 (38.8) • (SOFA-9)




2 0.09 (23.4) 0.04 (24.9)
ω 
V2
2 0.81 (52.0) 0.69 (41.5)
ω 
Q
2 0.66 (71.4) 0.64 (62.1)
Residual error
σ2 0.03 (18.2) 0.03 (18.1)
Performance measures
-2LL -879.7 -904.9
CL, clearance; CLcardiac failure, clearance for the cardiac failure group; V
1
 central volume; V
2
, peripheral volume; Q, intercompartmen-
tal clearance; ω2, variance, the square root of the exponential variance of η minus 1 is the percentage of interindividual variability in 
the pharmacokinetic parameters; σ2 , proportional intraindividual variance; values in parentheses are CV, coefficient of variation of
the parameter values; -2LL, objective function.
in ICU patients with cardiac failure are 1.6 times higher than that in patients without cardiac 
failure and only slightly different in ICU patients with an increasing SOFA score (ΔSOFA, 
6) receiving the same propofol infusion scheme of 2.5 mg/min (Figure 2).
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Table 3 Population pharmacodynamic parameters of the basic and the final model with the SOFA score as covariate
based on the Ramsay score.




-2.49 (-26.6) -0.12 (-757)
θ
2
1.61 (33.9) 1.62 (34.8)
θ
3
1.18 (17.2) 1.21 (18.1)
θ
4
1.38 (16.9) 1.44 (17.1)
θ
5
1.60 (10.2) 1.75 (9.9)
θ
6
 (propofol) -1.71 (-19.3) -1.34 (-26.8)
θ
7
 (SOFA) - 0.22 (38.2)
Interindividual variability



















 · SOFA); ω2, variance, 
the square root of the variance of η is the percentage of interindividual variability in the pharmacodynamic parameters; values in 
parentheses are CV, coefficient of variation of the parameter values; -2LL, objective function.
Pharmacodynamic model using the Ramsay as endpoint 
Five hundred and forty-one Ramsay observations were available for the model. A propor-
tional odds model, relating the probability of sedation to the propofol concentration was 
used to describe the pharmacodynamic data. With increasing SOFA score, increased levels 
of sedation were observed. The final parameter estimates are shown in Table 3. The basic
model predicted 31.7% correctly and 74.1% closely (i.e., within ± 1 Ramsay score). In the 
final model, these values were 39.7 and 84.4%, respectively. The diagnostic plots of the
naïve pooled observed probability and predicted cumulative probability at different SOFA 
scores are given in Figure 3. The results of the validation showed that the effect of the SOFA 
score could also be demonstrated in the population that was used for the external validation, 
with the percent of correctly predicted and closely predicted Ramsay scores increasing from 
35.8 to 39.4% and from 70.5 to 77.2%. Figure 4 shows the probability for Ramsay score 1 to 
6 as a function of the propofol concentration for the final model for critically ill patients with
different severity of illness (SOFA 3, SOFA 9, and SOFA 15). The propofol infusion rates, 
which are based on the pharmacokinetic model, necessary to achieve the desired sedation 
level are also shown in this figure. For example, if deep sedation is desired, Ramsay 5 is
most probable at infusion rates of 4.7 to 7.0 mg/min at SOFA 3, whereas with severe illness 
(SOFA 9 and 15), decreased infusion rates of 2.0 to 4.3 mg/min and less than 1.6 mg/min, 
respectively, are needed. At higher rates, the probability of Ramsay 5 deceases, and Ramsay 
6 is the most probable sedation score.
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Figure 4 Simulated probabilities for a particular 
Ramsay sedation score, based on the final model
with SOFA scores (A) 3 , (B) 9, and (C) 15 as a 
function of propofol concentration (mg/L) and 
infusion rates (mg/min).
Figure 3 Diagnostic plots showing the naïve pooled 
observed probabilities (closed circles) and predicted 
probabilities on Ramsay score ≥3, ≥4, and ≥ 5 of 
the final population model (open circles) vs. propo-
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Table 4 Population pharmacodynamic parameters for the basic and final model with the SOFA score as covariate for











, mg/l 2.59 (22.1) 5.14 (24.1) – (SOFA • 0.22 (26.6)) 7.53 (43.6) – (SOFA • 0.33 (49.7))








2 0.07 (10.8) 0.06 (10.5) 0.06 (10.4)
Performance measures
-2LL 46223.3 45905.7 45143.6 (16.7)
E
0
, baseline value equals 100 ; E
max
, maximal effect was assumed to be 100; EC
50
, propofol concentration at half the maximum score; 
SOFA, Sequential Organ Failure Assessment Score; γ, Hill coefficient;  ω2, variance, the square root of the exponential variance of η mi-
nus 1 is the percentage of interindividual variability in the pharmacodynamic parameters; σ
1
2 , proportional intraindividual variance; 
values in parentheses are CV, coefficient of variation of the parameter values; -2LL, objective function.
Pharmacodynamic model using the BIS as endpoint
The data set included 7159 BIS values from 26 critically ill patients, yielding a median of 
168 (36-737) observations per patient. Eighteen percent of all data and 85% of BIS values 
> 90 were associated with electromyographic activity > 42 dB.13 Depth of sedation was best 
described with a sigmoid Emax model with the SOFA score as significant covariate for the
EC50 (Table 4). The severity of illness influenced the level of sedation, shown by a highly
significant reduction in the -2LL from 1440 to 1384. The population parameters of the basic
and final pharmacodynamic model are reported in Table 4. The bootstrap validation (100
replications) confirmed the stability of the model. Figure 5 shows a median and a worse fit
of the level of sedation, the influence of the propofol concentrations, and the high residual
error. Figure 6 shows simulations of the influence of the severity of illness and cardiac
failure on the BIS, following a continuous propofol infusion rate of 2.5 mg/min. Table 5 
presents model-based propofol dose guidelines to achieve BIS values of 60 and 75, both of 
which have been correlated as values reflecting moderate sedation.13,14
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Figure 5 BIS vs. time (days) for a (A) median, and (B) 
worse performance. The open  circles represent the BIS 
observations, the solid lines represent the individual 
predicted observations, and the dashed lines 
represent the population predicted observations. The 
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Figure 6 Simulated values for the BIS with medians (solid lines) and 90th percentiles (dashed lines), following a 
continuous propofol infusion rate of 2.5 mg/min in critically ill patients (A) with cardiac failure (SOFA 9 ) and without 
cardiac failure for different SOFA scores (B) 9 , (C) 15, and (D) 3.
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Discussion
In this study, we demonstrate that severity of illness expressed by the SOFA score particu-
larly affects the pharmacodynamics and to a minor degree the pharmacokinetics of propofol 
in critically ill patients during long-term sedation. Additionally, cardiac failure (heart failure 
and complicated post-cardiopulmonary bypass surgery) influences the pharmacokinetics,
resulting in approximately 1.6-fold higher propofol blood concentrations (Figure 2). In par-
ticular, severity of illness accounts for large differences in the model-based dosing guide-
lines (infusion rate requirements, as shown in Table 5 and Figure 4). When critically ill 
patients are given the same propofol infusion scheme (e.g., 2.5 mg/min), the predicted level 
of sedation ranges from Ramsay 4 to 6 and the BIS value from 66 to 55 (Figure 6) when the 
severity of illness increases from SOFA 3 to 15.
The pharmacokinetic analysis revealed a 38% lower clearance in ICU patients with cardiac 
failure compared to critically ill patients without cardiac failure, and a smaller peripheral 
volume of distribution in ICU patients with a higher degree of illness. Evidence for need of 
lower dosages was found in patients with cardiac failure. In this group, three patients had 
undergone rethoracotomy due to hemorrhage after the coronary artery bypass graft surgery, 
which affects the hemodynamic status. One patient had a low cardiac output post-surgery 
and needed inotropics, and three patients with heart failure had a reduced ejection fraction 
of 20-30%, which may affect the hepatic perfusion and thus the clearance of propofol. 
Some evidence for a reduced clearance in cardiac patients was shown before in a study in 
children.15 No significant correlation was found between cardiac failure and intercompart-
mental clearance or peripheral volume of distribution. Although of relatively small clinical 
influence, an increasing SOFA score (more severe degree of illness, based on six organ
Cardiac failure Noncardiac failure patients
SOFA 9 SOFA 3 SOFA 9 SOFA 15
BIS target 60
   Infusion rate (mg/min) 1.6 3.7 2.6 1.6
   Blood concentration (mg/L) 1.28 1.78 1.28 0.78
   Ramsay score 5 4 5 5
BIS target 75
   Infusion rate (mg/min) 0.4 1.0 0.7 0.4
   Blood concentration (mg/L) 0.36 0.48 0.36 0.19
   Ramsay Score 4 2 4 5
Table 5 Dosing guidelines to achieve Bispectral index values of 60 and 75, based on simulations by the population 
pharmacokinetic-pharmacodynamic model of the current study, corresponding propofol blood concentrations and most 
likely to occur Ramsay scores.
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functions) was associated with a smaller peripheral volume of distribution. An explanation 
for this decrease may be that tissue perfusion is altered in severe illnesses. In contrast, 
the covariates renal failure, mean arterial blood pressure, and doses of dopamine and 
norepinephrine, which are items of the SOFA, were not independent significant covariates.
The pharmacokinetic parameters estimated by the current study were comparable to estimates 
in other studies.10,16,17 Our estimation of the peripheral volume of distribution (1140 L) was 
seven times larger than the previously reported peripheral volume of 168 L.10 This larger 
estimate may be a result of the longer duration of propofol administration, during which 
more extensive tissue distribution may have occurred.
The effects of propofol have been analyzed by a sigmoidal Emax model using the BIS and 
by a proportional odds model using the Ramsay score as pharmacodynamic endpoint. The 
BIS has been classified as ordinal or interval data, and up to now there is no consensus.18 
We choose to analyze the BIS as if it were a linear scale (parametric approach). The non-
parametric approach would require a large number of categories to model and most likely a 
substantial number of observations in all parts of the BIS scale. The BIS data were described 
adequately; however, the BIS showed a large scattering (Figure 5), which was reflected in
the large residual error of 24% (Table 4). This large residual error may be caused partly by 
excessive EMG activity and negatively affects predictions of correct dosing. This should be 
taken into account when the BIS monitor is considered for use in clinical practice.
The pharmacodynamics of propofol was significantly influenced by the severity of illness for
both the Ramsay and the BIS as pharmacodynamic endpoints. The probability for a deeper 
Ramsay score increases with progressive illness, which means that lower infusion rates 
suffice to maintain a discrete Ramsay score if the condition of critically ill patients worsens
(Figure 4). The influence of the severity of illness is also demonstrated in the external vali-
dation, in which the percentage of correct predictions increased after incorporation of this 
covariate. Using the BIS as a pharmacodynamic endpoint, the propofol infusion dose needs 
to be reduced up to 60% when the condition of an ICU patient worsens from SOFA 3 to 15 
(Table 5). In this study, there was no evidence for tolerance (a decrease in the effect of a drug 
over time or the need to increase the dose to achieve the same effect) in patients given long-
term propofol infusion. Tolerance of propofol has been reported by Buckley,19 but the fact 
that the need  for an increased dose was related to the improving condition of the patients 
was not ruled out. Our findings are important for clinical practice, because until now it has
been a common practice to aim at deeper sedation in more severely ill patients and conse-
quently to use a high infusion rate in the early course of the critical illness, followed by a 
downwards titration over time.20 Conversely, our results may indicate that ICU patients will 
need upwards titration over time with recovering. Specific dosing guidelines are given in
Table 5 and Figure 4.
In conclusion, this study illustrates that severity of the illness particularly influences the
pharmacodynamics and, to a minor degree, the pharmacokinetics of propofol in critically ill 
patients during long-term sedation. This means that with severe illness, infusion rates must 
be reduced. Furthermore,in patients with cardiac failure, the propofol dosages should be 
reduced by 38%.
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Liver blood flow, cardiac output and propofol pharmacokinetics
Abstract
Objective: To investigate the effect of the cardiac output and liver blood flow on propofol
concentrations in critically ill patients in the intensive care unit.
Methods: 5 medical/surgical critically ill patients were enrolled in this preliminary study. 
Liver blood flow was measured using sorbitol. The cardiac output was measured by bolus
thermodilution. NONMEM V was applied for propofol pharmacokinetic analysis.
Results: Clearance of propofol was positively influenced by the liver blood flow (P < 0.005), 
whereas no significant correlation between cardiac output and propofol clearance was found.
A correlation between liver blood flow and cardiac output or cardiac index, could not be
assumed in this patient group.
Conclusion: Liver blood flow is a more predictive indicator than cardiac output for propofol
clearance in critically ill patients. Further study is needed to determine the role of the liver 
blood flow and cardiac output on the pharmacokinetics of highly extracted drugs in order to
reduce high observed interindividual variabilities in response in critically ill patients.
Introduction
Propofol is a drug with a high hepatic extraction,1 which means that its clearance highly 
depends on liver blood flow. The hepato-splanchnic blood flow amounts to 25-30% of the
cardiac output (CO)2 and is influenced by different physiological conditions such as the
ingestion of food and exercise.3,4 Previous reports have shown the inverse relationship 
between the CO and propofol concentrations in animals and in relatively healthy surgical 
patients during anaesthesia.5-8 In critically ill patients, liver blood flow (LBF) and cardiac
output may vary widely, which may have a major impact on the pharmacokinetic profile of
drugs with flow-dependent clearance. Hypotensive patients with severe sepsis may have
low, normal or increased cardiac output.9 In patients with shock, blood flow to heart, brain
and muscle is maintained at the expense of renal and splanchnic blood flow. Hemodynamic
support, resuscitation and inotropic therapy10 can change the LBF/cardiac output ratio. 
Similar liver blood flow but higher COs have been shown in chronic hemodialysis patients
compared to healthy volunteers.11 In addition, mechanical ventilation can influence cardiac
output and liver blood flow.12,13
The aim of this pilot study was to explore the influence of variability in liver blood flow and
cardiac output on the pharmacokinetics of propofol in critically ill patients with different 
underlying disease. This is important, because it is known that there is a large unexplained 
interindividual variability in response of drugs in critically ill patients, which complicates 
dosing. The results of this pilot study also provide information on the relation between 




The study was approved by the local Ethics Committee of the St Antonius Hospital, Nieuwe-
gein, The Netherlands. Written informed consent was obtained from the patients’ relatives. 
Patients were eligible for participation in the study if a pulmonary artery catheter was 
inserted, were between 20-90 years, were expected to be mechanically ventilated and sedated 
with propofol for more than 2 days. Patients with known hypertriglyceridemia, history of 
drug abuse, allergic history to propofol or pregnancy were excluded as were patients with a 
known history of fructose intolerance or lactic acidosis. The patients of this sub study also 
participated in a larger study.14
Blood and urine sampling and analysis
Arterial blood samples (2 ml) for determination of propofol and sorbitol concentrations 
were collected in glass oxalate tubes. Propofol whole blood samples were stored at 4ºC and 
analysis was carried out within 2 weeks by high-performance liquid chromatography with 
fluorescence detection.15 The limit of quantification was 0.035 mg/l. Inter- and intra-assay
coefficients of variation were less than 9.6 % and 2.6% respectively over the concentration
range 0.5-5 mg/l. Sorbitol samples were taken before sorbitol administration and at 40 and 
45 minutes after the start of the sorbitol infusion. The samples were immediately kept on ice 
water until centrifuged within 30 minutes at 4ºC. Urine was collected during the start of the 
sorbitol bolus until 1 h after stopping of the infusion. Sorbitol plasma samples and aliquots 
of urine were stored at -20ºC. Sorbitol concentrations in plasma were measured with gas 
chromatography-mass spectrometry using the method of Jakobs C et al.16 The coefficient
of variance of 1.04 µmol/l was 22%, n=14. Sorbitol concentrations in urine were measured 
with capillary gas chromatography as described by Jansen G et al.,17 with a coefficient of
variance of 18% at 14 mmol/mol creatinine , n=44. 
LBF calculation
Liver blood flow was determined using the concentration of sorbitol at steady state.18,19 A 2 
gram loading dose of sorbitol 30% (Tilburg, The Netherlands) was given, followed by a 50 
mg/min infusion during 45 minutes.
Liver blood flow (LBF) was calculated according to Schoemaker et al.,20 using the following 
equations:
(1)
in which Ht is the hematocrit as sorbitol does not concentrate in the erytrocytes and CLH is 
hepatic sorbitol clearance. The extraction ratio E was assumed to be 0.96.3 Hepatic sorbitol 
clearance was assumed to be equal to the extrarenal clearance.
(2)
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Renal fraction was calculated as the total sorbitol excretion in urine divided by total dose 
administered. Total sorbitol excretion was calculated with the urine collected during the first
2 h (assuming excretion beyond 2 h was negligible). Total sorbitol plasma clearance was 
calculated as sorbitol infusion rate divided by the steady state plasma concentration.
From the equations follows:
(3)
Pharmacokinetic analysis
Pharmacokinetic parameter analysis of propofol was performed in NONMEM (Non-Linear 
Mixed effect Modeling) (GloboMax LLC, Hanover, MD, version V release 1.1) 21 by use 
of the first-order conditional estimation (Method 1) with η-ε interaction. Discrimination
between different models was made by comparison of the objective function. A value of 
P<0.005, representing a decrease of 7.8 points in the objective function, was considered 
statistically significant. In addition, goodness of fit plots including observations vs. 
individual predictions, observations vs. population predictions and weighted residuals vs. 
time and population predictions vs. weighted residuals were used for diagnostic purposes. 
Furthermore, the confidence interval of the parameter estimates, the correlation matrix and
visual improvement of the individual plots were used to evaluate the model. The pharma-
cokinetic parameters were tested for correlation with cardiac output, cardiac index (CI) and 
liver blood flow.
Cardiac output
Cardiac output was measured just before the sorbitol loading dose by using the gold standard 
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PEEP = positive end-expiratory pressure; PS = pressure support ventilation; PC = pressure control ventilation, EF= ejection fraction, 
SOFA = Sequential Organ Failure Assessment score on the day of study.24
Table 1 Patient characteristics.
Results
Five patients were included in this pilot study. The characteristics of the patients are presented 
in Table 1. Table 2 shows the calculated liver blood flow and the measured cardiac output
of the patients.
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1 2.47 3.16 0.78 29.3 1.660 0.027
2 1.56 3.09 0.50 49.8 1.003 0.0005
3 1.32 3.92 0.34 49.0 0.975 0.044
4 1.08 2.05 0.53 74.3 0.633 0.056
5 0.922 2.08 0.44 76.1 0.655 0.003
Table 2 Cardiac output and liver blood flow (LBF) of the studied patients.
Figure 1 The relationship of propofol clearance and liver blood flow.




















Propofol pharmacokinetics were adequately described by a two-compartment model, 
parameterized in terms of volume of the central compartment (V1), volume of the peripheral 
compartment (V2), the intercompartmental clearance (Q) and the elimination clearance 
(CL). The residual error was best described with a proportional error model. The clearance 
of propofol was significantly influenced by the liver blood flow (P < 0.005; objective 
function decreased from -134.9 to -142.9). Figure 1 shows the relationship between liver 
blood flow and the propofol clearance. The diagnostics of the final model are shown in
Figure 2. For propofol, clearance (SE) was 1.35(0.5) + (1.19(0.44) · (LBF – 1.32)) L/min 
with an interindividual variability (CV) of 17%. The central volume was 26.5 (SE 5.57) 
L, the peripheral volume 1350 (SE 530) L and the intercompartmental clearance 1.87 (SE 
0.34) L/min (CV of 42%). The residual error was 13%. Figure 3 shows a simulation of the 
predicted propofol concentrations at two different LBFs. The simulation illustrates two-fold 
higher propofol concentrations when the LBF decreases from 2.45 to 1.32 L/min.
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Figure 2 Diagnostic plots of (A) measured propofol concentrations vs. individual predicted  and (B) measured propofol 
concentrations vs. population predicted concentrations by the final model, superimposed on the line x=y (line of
identity).
Figure 3 Simulated propofol concentrations following continuous infusion of 2.5 mg/min in critically ill patients with 
liver blood flow (LBF) of 1.32 and 2.45 L/min.
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No significant correlation between cardiac output or cardiac index and propofol clearance
was found. A correlation between liver blood flow and cardiac output or cardiac index, could
not be assumed on the basis of the available data (Table 2).
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Discussion
Our results of this pilot study (n=5) suggests that liver blood flow was a more predictive
indicator than cardiac output for propofol pharmacokinetics and presumably also for other 
highly extracted drugs. A significant relationship between liver blood flow and propofol
clearance was found, whereas the relation to cardiac output was not clear. Higher liver blood 
flows increased the rate of propofol clearance and resulted in lower propofol concentrations
(Figure 3). The impact of CO on propofol pharmacokinetics in these critically ill patients 
was not statistically significant. Although a higher CO roughly implied higher liver blood
flows, its relation could not be specified or predicted from the LBF (Table 2). One reason
for the lack of correlation between these parameters could be the quality of measurement of 
CO, as previous studies have highlighted high levels of ignorance in the understanding of 
the use of the pulmonary artery catheter.22,23 However, the physicians in our clinic have high 
expertise in the use of this catheter, allowing for reliable CO measurements in our patients. 
It seems therefore that the relation between CO and LBF in critically ill patients is complex 
and deserves further study.
A wide range of hepatic sorbitol clearances, which reflects the liver blood flow was noted
in our patients, ranging from 0.63-1.66 L/min. For healthy volunteers the hepatic plasma 
clearance was found to be 0.77 L/min18 and 1.00 L/min11,18 and showed low interindividual 
variability (± 0.18, n=6 and ± 0.22 L/min, n=11, respectively). The broad range in liver 
blood flow in our five patients is accompanied by different diagnoses and levels of organ
failure, characterizing the special group of critically ill patients. This large variability has 
important consequences for dosing of propofol and probably other flow dependent drugs.
In previous studies, sorbitol has proven to be a suitable marker to assess the liver blood flow,
having the advantage that the extraction ratio is higher and better preserved in liver diseases 
compared to the commonly used marker indocyanine green (ICG) and therefore may be 
more accurate.3,20 However, the method is not ideal for standard care, because of its duration 
of administration and its method of analysis.
In conclusion, insight in liver blood flow is an important determinant to optimize the propofol
dosing and prevent oversedation. Further study is needed to determine the exact role of the 
liver blood flow and cardiac output and its influence on the pharmacokinetics of propofol
and other flow dependent drugs in critically ill patients.
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Population PK-PD modeling of propofol 
and midazolam in children and 
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The overall goal of the investigations described in this thesis was to develop novel strategies 
to individualize dosing of propofol and midazolam in infants and in critically ill patients, 
on the basis of population pharmacokinetic-pharmacodynamic (PK-PD) modeling. In the 
investigations the emphasis was on the modeling of the influence(s) of the covariates age,
severity of illness and organ failure on the pharmacokinetics and the pharmacodynamics.
Providing adequate, predictable and safe sedation in (pediatric) intensive care patients is still 
a problem. In addition to the fact that agitation significantly and adversely affects patient
outcome, there is increasing evidence that over sedation may be an even larger problem 
associated with worse sequelae.1 However, due to the high variability in dose requirements 
and reports on adverse events following propofol doses higher than advised according to 
the product characteristics, dosing is complicated.2,3 This underscores the importance of 
developing rational dosing schemes for individual patients. In this context population phar-
macokinetic-pharmacodynamic modeling constitutes a sophisticated research tool.
Sedation in pediatrics
During childhood, many physiological changes take place, especially during the first two
years of life with dynamic changes in organ structure and function, which have an impact on 
the pharmacokinetics and pharmacodynamics of drugs.4 In the investigations described in 
this thesis the sedatives propofol and midazolam were studied in a population of relatively 
healthy nonventilated infants aged 3-24 months following elective craniofacial surgery.
Propofol is widely used for anaesthesia in pediatrics, because of its short duration of action 
and the rapid onset of the effect. However, sedation with propofol in children has been 
controversial, because of reports on the so-called “propofol infusion syndrome”, defined
as bradycardia, lipemia, metabolic acidosis and rhabdomyolysis after use at high doses 
(≥ 4 mg · kg-1 · h-1) and for long durations (> 48 h).2,3 Children are often exposed to risks of 
adverse reactions by lack of information from dedicated studies on the pharmacokinetics 
and pharmacodynamics in this particular age group. This forces clinicians to extrapolate 
data from adults to children and to prescribe outside the terms of product license. As only 
25-50% of drugs delivered to children are licensed for this population,5,6 studies in children 
in various age-groups are nowadays encouraged and supported by the European Regulation 
Authority from early 2007.
In Chapter 2 the safety of propofol in children in the paediatric intensive care unit (PICU) 
was evaluated on the basis of serum triglycerides, creatine phosphokinase, blood gases 
and physiological parameters. No adverse events were observed, when using dosages 
< 4 mg · kg-1 · h-1 during short-term sedation (median of 11 h). In Chapter 3 dosing guide-
lines were developed for propofol using population pharmacokinetic and pharmacodynamic 
modeling. The population of nonventilated, relatively healthy infants aged 3-17 months 
was characterized by a markedly high propofol clearance of 0.70 L/min standardized to a 
128
Chapter 8
median body weight of 8.9 kg, which was two times higher than reported in the literature 
for ventilated children and for adults7-9 and a high central volume of 18.8 L. Bodyweight 
was found to influence the clearance by CL = 0.70· (BW/8.9)0.61 L/min. These two pharma-
cokinetic findings explain why pharmacokinetic models for patients aged 2-88 years during
anesthesia7 and for children after cardiac surgery8,9 over predict the propofol concentrations 
and can therefore not be used in the population of nonventilated relatively healthy sedated 
infants. Interestingly our model was found to correctly predict propofol concentrations in 
the group of children studied by Murat et al.,10 who gave a bolus dose of 4 mg/kg to sponta-
neously breathing children with burns with a median age of 15 (12-31) months and a median 
weight of 11.2 (8.7-18.9) kg (data not shown). As relatively healthy ventilated children un-
dergoing anesthesia7,11 did show a lower estimate of the clearance, this underlines that apart 
from the state of health, spontaneous breathing may also be a determinant for the selection 
of initial dose regimens. This also implies that caution is needed to extrapolate outside the 
studied covariate range, even within the same age-group. Compared to adults8,12 the observed 
higher clearance of propofol may physiologically be explained by the higher liver weight 
(and the corresponding hepatic blood flow) as a fraction of bodyweight, which gradually
decreases during maturation from about 3.6% at birth to about 2.4% in normal adults.13 The 
higher infusion rates that are required as a result of the differences in the pharmacokinetic 
parameters may even explain why the propofol infusion syndrome is more often observed in 
children than in adults. Dosages up to 10.7 mg · kg-1 · h-1 for sedation of critically ill children 
have been described to result in fatalities.14 The (pharmacodynamic) sensitivity of infants 
to propofol appears to be comparable to adults. We reported EC50 values of 3.71 mg/L in 
infants, which are comparable to previous published values of 3.91 mg/L15 and 3.16 mg/L in 
adults (Chapter 6). A large pharmacodynamic interindividual variability and residual error 
were observed on the COMFORT-behavior score (COMFORT-B) (47% and 32%, respec-
tively) and Bispectral index (BIS) monitor (145% and 13 BIS units, respectively), without a 
pertinent covariate which could account for this variability. The considerable variability and 
the safety concerns emphasize the importance to further study possible covariates influencing
the PD of propofol. In the meantime, dose titration of propofol is important whereby doses 
should not exceed 4 mg · kg-1 · h-1.2,3
In Chapter 4, we developed dose regimens for midazolam in nonventilated infants under 
the age of 2 years in the PICU. Midazolam is still the most commonly used sedative in 
children. However, paradoxical reactions are not uncommon. Midazolam has an intermediate 
extraction ratio and its elimination is almost exclusively mediated by CYP3A4/5 and to a 
lesser extent by CYP3A7. For this reason, midazolam is often used as a model drug for 
the evaluation of CYP3A4/5-dependent hepatic clearance.16,17 Comparable to the results 
on propofol in Chapter 3, midazolam clearance was remarkably high. The estimated total 
clearance of midazolam of 157 ml/min (16.7 ml · kg-1 · min-1) in nonventilated children in 
our study was 3 times higher than clearance described in ventilated critically ill children 
(6.0118 and 5.0 ml · kg-1 · min-1 19) and was also slightly higher compared to the values in 
nonventilated children aged 6 months to 2 years (11.3 ml · kg-1 · min-1).20 Reported clearance 
values in ventilated critically ill adults are 188 ml/min (2.7 ml · kg-1 · min-1)21 and in non-
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ventilated healthy adults 523 ml/min (7.6 ml · kg-1 · min-1).22 Clearance in our study tended 
to be related to age, but the relatively small number of infants older than 15 months may 
explain why this trend did not reach statistical significance. Generally, it can be expected
that midazolam clearance values are related to the degree of enzyme maturation and liver 
weight. Midazolam is only marginally metabolized by CYP3A7, which is predominantly 
expressed in the fetal liver and of which the activity decreases immediately after birth to 
approximately 10% of newborn levels between 6 and 12 months of age. During the first
year of age, CYP3A4 activity increases gradually.23,24 The expression of CYP3A5 was found 
to be independent of age.24 The unpredictable sedation levels observed in clinical practice 
requiring titration of midazolam dosages, was reflected by the observed wide interindividual 
variability in pharmacodynamics and the high residual error. The interindividual variabil-
ity was found to be 89% on the COMFORT-B and 66% on the BIS for the infants whose 
response on midazolam could be characterized on the BIS, which was only in 43% of the 
patients. The residual error was found to be 31% on the COMFORT-B and 13 units on 
the BIS. None of the studied patient characteristics could explain these variabilities. This 
implies that children between 3 and 24 months should receive the same initial dose after 
which titration remains important. Concerning the observed trend in clearance with age, the 
dosing regimens may be less appropriate for infants aged 15-24 months, requiring further 
study in a wider age range.
When comparing the results of the PK-PD model of propofol (Chapter 3) and midazolam 
(Chapter 4), propofol may be preferred over midazolam because of the lower interindividual 
variability in pharmacodynamics compared to midazolam (47% vs. 89%), which is recog-
nized in clinical practice. Although this implicates preference for the use of propofol over 
midazolam, its use for sedation in children is formally still prohibited because of safety 
concerns. However, by limiting the propofol infusion rates up to 4 mg · kg-1 · h-1 during 
less than 48 h propofol and by monitoring of safety parameters as bradycardia and lipemic 
blood, propofol may be a favourable alternative for midazolam, especially in children 
who experience paradoxical responses to midazolam, who have renal failure or during co-
administration of interacting drugs.
Sedation in critically ill patients
In the Chapters 6 and 7, propofol was studied in the population of critically ill adult patients 
during long-term sedation (0.7-9.5 days). These patients are typically characterized by high 
variability in dosing requirements, while fatalities have been reported after long term ad-
ministration (> 36 h) of high doses (> 5.5 mg · kg-1 · h-1).2 Evidence is now emerging that 
the sedative strategy is important in determining the patient outcome. Sedation protocols 
and daily interruption of sedation demonstrated reductions in the duration of ICU and 
hospital length of stay, duration of ventilation and demonstrated improved psychological 
functioning.1,25-27 Therefore, in the investigations propofol doses were titrated by the nurses 
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to the physician determined optimal Ramsay score using a protocol-driven approach.
In Chapter 5, we showed that actual clinical sedation practice significantly differed from
sedation guidelines, as evidenced by a consistent significantly (P < 0.001) deeper level of 
sedation titrated by the nurses than targeted by the physician in long-term sedated critically 
ill patients. The intention of sedation guidelines to improve the patients’ outcome25,26 may 
therefore be not fully achieved in current practice. The low median numbers of propofol 
dose adjustments per day (2.2) indicate a tendency to keep the infusion rate constant. More 
frequent daily reevaluation of the achieved sedation level in the multidisciplinary meeting 
to allow for feedback from the primary care nurse is indicated, which may result in either 
“deeper” target levels or “lighter” actual levels.
Another aspect of this study was to explore the utility of the BIS. Between the Ramsay and 
the BIS, a moderately significant correlation (r= -0.570) was found. In over sedated patients
(difference between the observed and target Ramsay score ≥ 2 points), low BIS values of 
less than 60, often associated with deep sedation28,29 were recorded in 78% of the critically 
ill patients. It seems therefore that for deeply sedated patients (Ramsay 5 and 6), the BIS 
may be added to the standard sedation monitoring instruments in order to prevent over 
sedation. This should be evaluated in further studies. For moderate and light sedation, the 
clinical assessment scales, although subjective, remain preferred, because the BIS showed 
shortcomings,30,31 such as EMG interference (Chapter 6),32 low sensitivity to midazolam in 
children (Chapter 4), high residual error which negatively affects predictions (Chapter 3, 4 
and 6) and reported influence of environment33 and neurological status.34,35 The direct effect 
of opioids on the BIS is still controversial. However, opioids can influence BIS monitoring
by enhancing the effect of sedatives.36,37 The lower sedative requirements and hence higher 
recorded BIS values may lead to oversedation when titrating to the same BIS values.38 In 
Chapter 3, the total dose of fentanyl administration during surgery was no covariate for the 
pharmacodynamic parameters. In Chapter 6, morphine dose was no significant covariate
for the PK of propofol. In general, pain is difficult to assess in the non-communicative
critically ill patients, because the gold standard (self report) is not possible, and this will 
therefore need further attention and research. The design of PK-PD interaction models for 
analgesia and sedation in critically ill patients may allow for more precise dosing guidelines 
and different target BIS values. Furthermore, since the concept of providing analgesia first
supplemented by sedation, provided a more satisfactory sedation level than the sedation 
based approach, especially in patients requiring significant respiratory support,39 incorpora-
tion of this concept in the sedation protocol (Chapter 5) may be advisable.
In Chapter 6, dosing guidelines for propofol in long-term sedated critically ill patients were 
provided using pharmacokinetic and pharmacodynamic modeling. Propofol clearance in the 
critically ill adult patients with cardiac failure was 62% of the value in patients without 
cardiac failure (1.28 L/min vs. 2.05 L/min). Although of relatively small value in clinical 
practice, an increasing Sequential Organ Failure Assessment (SOFA) score (degree of illness, 
based on 6 organ functions) was associated with a smaller peripheral volume of distribu-
tion expressed as V2 = 1140 – 55.4 · (SOFA-9). However, severity of the illness was found 
to be a major determinant of the level of sedation, using the Ramsay score (proportional 
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odds model) and the Bispectral index (Emax model) as pharmacodynamic endpoints. Large 
differences in the model-based dosing guidelines were found, indicating lower propofol 
dosing requirements with increasing severity of illness. There was no evidence for tolerance 
(a decrease in the effect of a drug over time or the need to increase the dose to achieve the 
same effect), which has been reported before, although the authors of that report did not rule 
out the possible relation to patients’ improving condition.40,41 The role of disease severity as 
a determinant of the pharmacodynamics is an important finding for the clinical setting, since
the condition of critically ill patients can change quickly and it is now common to aim at 
deep sedation levels in severely ill patients with volume or pressure controlled ventilation 
or prone position. Especially since we have noted in Chapter 5 that nurses do not adhere to 
sedation protocols and favour the lock-in principle of maintaining (too high) infusion rates, 
lower initial dosages should be recommended during severe illness. Additional improve-
ments in clinical outcomes associated with incorporation of initial dosing PK-PD dosing 
guidelines should be identified, showing that there is still much work to do.
For critically ill patients, another important covariate that accounts for differences in dose 
requirement between patients was identified in a preliminary study in Chapter 7. Liver 
blood flow, as determined by sorbitol administration, was found to be a significant covariate
for the clearance of propofol expressed by CL = 1.35 + 1.19 · (LBF-1.32) L/min. It was 
also shown that in this patient group, variability in hepatic blood flow was unrelated to
variability in cardiac output. The role of the cardiac output and liver blood flow on the
clearance requires further investigation. Given that propofol is a high-extraction drug, which 
makes its clearance primarily dependent upon liver blood flow, identified covariates for the
clearance may be representative for other high clearance drugs.
Perspectives: sedation in neonates
The ultimate goal of the development of PK-PD models is not only to develop dosing guide-
lines for the studied population, but also to predict the time course of the concentration and 
the effect in populations in which no information is yet available, thereby providing initial 
guidelines for a safe and effective dose regimen, which could also serve as a starting point 
for dedicated investigations. In this context it is of interest to explore the predictive value of 
developed models in the youngest group of children, namely neonates. The group of neonates 
is hardly studied, because of ethical and practical constraints with regard to blood sampling. 
As a result many drugs are not labelled for use in neonates. It is therefore of considerable 
interest to use modeling and simulation in neonates, as a starting point for the design of 
limited confirmatory clinical studies. Recently, safety concern was raised for use of anes-
thetics including propofol in neonates, after the report that the administration may increase 
apoptotic neurodegeneration in the developing rat brain.42 Further study showed that the 
administered dose may be an important factor in the induction of neurodegeneration43 and 
that these high doses would be not achieved in clinical practice. To provide a starting point, 
132
Chapter 8
the prospective use of three published population PK models for propofol in children is 
explored by comparison of population predicted propofol concentrations with corresponding 
measured concentrations. The details of the three population PK models are summarized in 
Table 1.
For evaluation of the predicted concentrations, actual data from nine preterm and term 
neonates admitted to the Neonatal Intensive Care Unit in the University Hospital Gasthuis-
berg, Leuven, Belgium, who received a bolus dose of 3 mg/kg propofol just before removal 
of the chest tube,46 were used. In patients of this investigation the median postmenstrual age 
was 36 (27-43) weeks, the median postnatal age 11 (4-25) days and the median weight was 
2.42 (0.91-3.8) kg. A median of 8 (7-9) arterial blood samples were obtained up to 8 (3-24) 
h after the bolus dose.
Figure 1 shows the observed propofol concentrations vs. predicted concentrations of the 
three pharmacokinetic models. According to this figure, neonates at a postnatal age younger
than 11 days (4, 7, 7, 8 and 11 days, respectively) appeared to be a distinctly different group, 
in which systematically higher propofol concentrations were observed compared to neonates 
with postnatal age older than 14 days (14, 17, 25 and 25 days). Moreover the cross species 
allometric model (A), which in the past has been used successfully for cross species extrapo-
lation of propofol pharmacokinetics44 systemically underpredicted propofol concentrations 
in neonates younger than 11 days, whereas from 14 days postnatal, the model performed 
reasonably well. Similar observations were obtained with the allometric model from infant 





Rats, 6 children aged 1-5 years 
following cardiac surgery and 
adults
CL, L/min = 0.071 × BW 0.78 
V
1
, L = 0.30 × BW 0.987
Q, L/min = 0.062 × BW 0.73
V
2





35 children aged 4 months to 
9 years undergoing general or 
urinary surgery 
CL, L/min = 0.185 ×(BW/13.7) 0.75
V
1
, L = 7.41 × (BW/13.7)
Q
2
 ,L/min = 0.614 ×(BW/13.7) 0.75 
V
2
, L = 54.6 × (BW/13.7)
Q
3
, L/min = 0.692 ×(BW/13.7) 0.75 
V
3




21 critically ill ventilated children 
aged 1 week to 12 years
CL, L/min  = 0.0302 × BW 
V
1
, L = 0.584 × BW
Q
2
, L/min = 0.016 × BW
V
2
, L = 1.36 × BW 
Q
3
, L/min = 0.0133 × BW
V
3
, L = 103 + 5.67 × BW
Table 1 Explored pharmacokinetic models for predictive value in neonates .
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Figure 1 Predictive performance in neonates by presentation of observed vs. population predicted propofol 
concentrations based on allometry, cross species44 (A), allometry from infant to child45 (B), and the per kg model9 (C) for 




to child (B)45 and the per kg model of Rigby-Jones et al., (C)9 indicating a distinctly different 
pharmacokinetic behaviour for the two age groups. Compared to the allometric models (A 
and B), the per kg model (C) showed more over prediction of the propofol concentrations 
for the older neonates and was more precise for the younger neonates. Therefore, allometric 
scaling may be suitable from 14 days postnatal age, but can not be used for the youngest 
neonates. An explanation of the inaccurate prediction may be that it takes a week or longer 
after birth for spontaneous closure of the ductus venosus. In the fetus, this shunt allows oxy-
genated blood from the placenta to bypass the liver to the systemic circulation for distribution 
to the rest of the body. Another explanation may be an immaturity of the UGT1A9 activity, 
which mediates 60% of propofol elimination by direct glucuronidation in the adult. It cannot 
be excluded that during the first 14 days of life liver blood flow plays only a minor role in
the elimination of propofol neonates and that the intrinsic clearance may be more important. 
Data on UGT1A9 activity in children as a function of age are yet not available.47
From this exploration, it can be concluded that although caution is needed in extrapolating to 
distinctly different populations, allometric scaling seems to predict propofol concentrations 
reasonably well in neonates from 14 days of age. Additional data from neonates are needed 
to refine existing models by determining the exact relation between patient characteristics
as age or bodyweight and specific pharmacokinetic and ultimately pharmacodynamic
parameters to provide individualized dosing regimens.
In conclusion, in this thesis dosing guidelines were provided for propofol and midazolam in 
the special group of infants and critically ill patients, on the basis of population pharmaco-
kinetic-pharmacodynamic (PK-PD) modeling. Part of the interpatient variability has been 
explained with covariate analysis by bodyweight, cardiac function, severity of illness and 
liver blood flow and unexplained interindividual variability has been characterized, which
will be essential for optimizing quality of sedation in clinical daily practice and improving 
patients’ outcome. Using population PK-PD modeling, clinical questions can be answered 
even in pediatric populations by circumventing restrictions in sampling amount. In the future, 
the vulnerable group of neonates should be further studied for safe and more appropriately 
prescribing dosages.
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Sedatie vormt een essentieel onderdeel van de zorg van patiënten op de (kinder) intensive 
care (IC). Sedatie kan angst en agitatie verminderen en eventuele kunstmatige beademing 
vergemakkelijken. Het standpunt met betrekking tot de ideale diepte van sedatie is in de 
afgelopen jaren gewijzigd van diepe sedatie in combinatie met spierrelaxantia naar lichte 
sedatie. De ontwikkeling van nieuwe beademingstechnieken en nieuwe inzichten in de 
negatieve effecten van oversedatie hebben daarbij een belangrijke rol gespeeld. Inadequate 
sedatie kan levensbedreigende agitatie veroorzaken met als gevolg bijvoorbeeld auto-
extubatie. Aan de andere kant, kan overmatige diepte van sedatie leiden tot een hogere 
morbiditeit en het voor de patiënt onmogelijk maken om te communiceren. Inmiddels is 
eenduidig vastgesteld dat oversedatie het verblijf op de IC onnodig kan verlengen. Dagelijks 
onderbreken van de infusie van sedativa blijkt de duur van mechanische beademing en het 
verblijf op de ICU te verkorten. Ook het gebruik van geprotocolleerd werken heeft invloed 
op de duur van mechanische beademing en de lengte van verblijf.
Hoewel er inmiddels richtlijnen zijn ontwikkeld voor sedatie, blijkt dat in de praktijk de 
sedatie vaak niet optimaal is en dat patiënten in het algemeen nog teveel sedativum krijgen. 
Een van de redenen is de hoge mate van variabiliteit in benodigde doseringen van sedativa. 
Het toepassen van de juiste doseringsschema’s vereist kennis van de  intra- and interindivi-
duele variatie in farmacokinetiek en -dynamiek om doseringen te individualiseren. Een be-
langrijk hulpmiddel in dit verband zijn zgn. covariaten waarmee de variabiliteit kan worden 
verklaard.
In dit proefschrift wordt populatie farmacokinetische (PK) en farmacodynamiche (PD) 
modeling gebruikt om richtlijnen te ontwikkelen voor de geïndividualiseerde dosering van 
de sedativa propofol en midazolam in de populatie van kinderen en van kritische zieke 
patiënten. De nadruk ligt op de rol van leeftijd, orgaanfalen en mate van ziekte als oorzaken 
van intra- en interindividuele variabiliteit.
Sedatie in kinderen
In de huidige praktijk is midazolam het sedativum van eerste keuze bij kinderen. Echter, in 
vergelijking met midazolam heeft propofol een aantal voordelen als 1) een korte halfwaar-
detijd, waardoor de dosering gemakkelijk te titreren is, 2) farmacokinetiek die onafhankelijk 
is van de lever- en nierfunctie en 3) het feit dat bij stoppen van de toediening de patient snel 
ontwaakt. Ondanks het feit dat propofol veel en met succes wordt toegepast op de volwassen 
intensive care, is begin jaren ’90 het gebruik van propofol bij sedatie van kinderen op de 
intensive care ter discussie komen te staan na het verschijnen van een aantal publicaties over 
gevallen van ernstige bijwerkingen waarvan enkele met fatale afloop. Toch wordt propofol
bij jonge kinderen op de ICU regelmatig toegepast als andere middelen niet toereikend 
zijn. Kinderen worden vaak blootgesteld aan risico’s bij gebrek aan gegevens over de juiste 
dosis, werking en bijwerking in kinderen, waardoor doseringen meestal op een betrekkelijk 
empirische manier worden geëxtrapoleerd vanuit volwassenen. Hierbij wordt dan geen 
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rekening gehouden met het feit dat de functie van de organen afwijkend kan zijn. Non-
lineair Mixed Effect Modeling (NONMEM) is met name geschikt voor PK-PD onderzoek 
bij kinderen, onder meer omdat er relatief weinig waarnemingen per individu nodig zijn om 
intra- en interindividuele variabiliteit in farmacokinetiek en farmacodynamiek te beschrijven 
en te verklaren. 
In het Erasmus MC-Sophia worden jaarlijks 50 à 60 kinderen onder de leeftijd van 2 jaar 
geopereerd vanwege afwijkingen aan de schedel. Door vochtophoping rondom de ogen, het 
gescheiden worden van de ouders en de stress van het verblijf op de intensive care worden 
de peuters postoperatief vaak onrustig, waardoor sedatie noodzakelijk is. 
Om te komen tot rationele doseeradviezen voor veilig gebruik van midazolam en propofol 
voor de sedatie van niet-beademde kinderen na uitgebreide craniofaciale chirurgie op de 
intensive care in, is de veiligheid bestudeerd (Hoofdstuk 2) en zijn er populatie PK en PD 
modellen voor propofol en midazolam opgesteld (Hoofdstukken 3 en 4). In deze studies 
werden de effecten van beide sedativa gekwantificeerd op basis van COMFORT-behavior
schaal (COMFORT-B) en de Bispectal index (BIS). De COMFORT-B bestaat uit 6 items; 
alertheid, kalmte, huilen of ademhalingsreactie, spierspanning, lichaamsbeweging en 
gezichtsspanning, en varieert van 6 (geen onrust) tot 30 (ernstige onrust). De BIS is een 
parameter die is afgeleid van het Electro Encephalo Gram (EEG), maar die (nog) niet is 
gevalideerd voor kinderen < 1 jaar. De numerieke waarde van de BIS varieert van 0 (geen 
cerebrale activiteit) tot 100 (volledig wakker). De resultaten in Hoofdstuk 2 laten zien dat 
er bij een dosering van propofol tot 4 mg·kg-1·uur-1 gedurende een mediane duur van 11 
u, de serum triglyceride concentraties en de creatininekinase activiteit niet zijn gestegen. 
Ook zijn er geen metabole acidose, temperatuurstijging of andere ongewenste bijwerking 
geconstateerd. Op basis van de populatie farmacokinetische analyse van het beloop van de 
propofol concentraties kon worden vastgesteld dat de farmacokinetiek van propofol in deze 
patienten het beste kan worden beschreven met behulp van een 2-compartimenten model 
waarbij lichaamsgewicht een covariaat is voor de klaring (Hoofdstuk 3). De populatie 
gemiddelden van de waarden van de farmacokinetische parameters zijn Cl = 0.70 · (BW/
8.9)0.61 l/min, V1 = 18.8 l, Q = 0.35 l/min and Vss = 146 l met een interindividuele variabiliteit 
van respectievelijk 20% voor Cl en 145% voor Vss. De gevonden klaring was 2x zo groot 
vergeleken met de waarden in de literatuur voor beademde kinderen en volwassenen. Dit 
verschil kan mogelijk verklaard worden door de verder gezonde conditie van de patiëntjes en 
het ontbreken van effect van beademing op de leverdoorbloeding. De propofol concentratie 
bij 50% van het maximale effect (EC50) was 1.76 mg/l met een interindividuele variabiliteit 
van 47% op de COMFORT-B schaal en 3.71 mg/l met interindividuele variabiliteit van 145 
% op de BIS schaal. Er kon geen invloed van patientkarakteristieken (covariaten) op de 
waarden van de PD parameters worden vastgesteld. Omdat de EC50 vergelijkbaar was met de 
EC50 van volwassenen, lijkt het dat kinderen vooral hogere doses propofol nodig hebben op 
basis van verschillen in farmacokinetiek en niet door verschillen in farmacodynamiek. Op 
grond van het populatie model adviseren we een propofol dosering van 30 mg/u voor een 
patiënt van 10 kg voor een COMFORT-B van 12-14 en een BIS van 70-75. Grote farmaco-
dynamische variabiliteit benadrukt de noodzaak tot verdere titratie.
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Samenvatting
De farmacokinetiek van midazolam kon het beste worden beschreven met behulp van een 
2-compartimenten model voor midazolam en een 1-compartimenten model voor de metabo-
lieten (Hoofdstuk 4). De onderzochte covariaten verbeterden de voorspelbaarheid van het 
model niet significant. De populatie gemiddelden van de belangrijkste farmacokinetische
parameters van midazolam zijn: een totale klaring van 0.157 l/min, V1 = 3.8 l, V2  = 30.2 
l, Q = 0.30 l/min, V3 = 6.69 l, Cl2 = 0.21 l/min, V4 = 1.69 l, Cl 3 = 0.047 l/min met een 
interindividuele variabiliteit van respectievelijk 54% voor Cl1, 82 % voor V2, 26% voor 
Cl2, 135% voor V4 en 42% voor CL3. De EC50 van midazolam was 0.58 μmol/l met een 
interindividuele variabiliteit van 89% op de COMFORT-B schaal. In 57% van de patiëntjes 
kon geen effect van midazolam worden geïdentificeerd op de BIS. De EC50 van de patiëntjes 
waarbij een midazolam effect kon worden aangetoond  was 0.63 μmol /l met interindividuele 
variabiliteit van 66 %. Op basis van het populatie model adviseren we startdosering van 1 
mg, gevolgd door een continu infuus van 0.5 mg/u voor een COMFORT-B van 12-14 voor 
een kind van 1 jaar. Door de grote farmacodynamische variabiliteit zal titratie noodzakelijk 
zijn.
Op basis van de resultaten in de Hoofdstukken 3 en 4 kan worden geconcludeerd dat op grond 
van de waargenomen verschillen in interindividuele variabiliteit propofol een beter voor-
spelbaar effect heeft dan midazolam. Vervolgonderzoek met behulp van populatie PK en PD 
modeling in kinderen is nodig om variabiliteit in effect verder te verklaren en waar mogelijk 
de doseringen verder te individualiseren om veilig gebruik in kinderen te garanderen.
Sedatie in kritisch zieke patiënten
Bij ernstig zieke patiënten is er sprake van een hoge variabiliteit in de benodigde doserin-
gen van sedativa, zowel tussen patiënten onderling als binnen een en dezelfde patiënt als 
gevolg van o.a. verschillen in hemodynamiek en orgaanfunctie. Volgens de richtlijnen van de 
Society of Critical Care Medicine is propofol 2e keuze sedativum vanwege de mogelijkheid 
tot het optreden van hypertriglyceridemie bij langdurig gebruik van Propofol 1%. In dit 
verband is van belang dat ook bij volwassenen gevallen zijn gemeld van het propofol infusie 
syndroom bij gebruik van hoge doseringen propofol.
In de studies die gericht waren op het ontwikkelen van doseeradviezen voor veilig en 
effectief gebruik van propofol bij langdurige toediening is er gebruik is gemaakt van een 
sedatieprotocol. Het gebruik van een sedatieprotocol wordt aangeraden in de richtlijnen om 
de duur van mechanische ventilatie en de lengte van verblijf te verkorten.
In hoofdstuk 5 wordt de effectiviteit van het gebruik van een sedatieprotocol geëvalueerd. 
De diepte van de sedatie werd daarbij bepaald op basis van de Ramsay sedatie score (een 6-
puntsschaal). De resultaten van dit onderzoek laten zien dat verpleegkundigen geneigd zijn 
dieper sederen dan is aangegeven door de intensivist-anesthesist (P < 0.001). Slechts 28% 
van de bestudeerde patiënten was correct getitreerd en 33% van de patiënten werd over-
gesedeerd. Opvallend was dat verpleegkundigen vooral geneigd zijn de eenmaal gekozen 
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doseringen te handhaven, ook bij oversedatie. Het voordeel van een sedatieprotocol zal 
hierdoor mogelijk niet worden bereikt. Als secundair doel is in deze studie ook ook gekeken 
naar de waarde van het sedatieinstrument de BIS in vergelijking met de Ramsay score. De 
Ramsay en de BIS waren matig gecorreleerd. De gemiddelde BIS waardes waren 93, 75, 55 
voor de groepen agitatie, lichte sedatie (Ramsay 2-4) en diepe sedatie (Ramsay 5-6).
In hoofdstuk 6 wordt het onderzoek beschreven naar de interindividuele variabiliteit in farma-
cokinetiek en farmacodynamiek van propofol in kritisch zieke patienten. De propofol PK 
data konden adequaat beschreven worden met een 2-compartimenten model, waarbij gecom-
pliceerde harten een 38% lagere klaring hebben (1.28 vs. 2.05 L/min) . De mate van ziekte, 
beschreven door de Sequential Organ Function Assessment (SOFA) score, waarbij punten 
worden toegekend bij orgaansystemen die falen, was geassocieerd met het verdelingsvolume 
van propofol (V2= 1140-55.4 [SOFA-9]), hetgeen echter klinisch van relatief weinig waarde 
is. De PD data, gekarakteriseerd op de Ramsay schaal werden beschreven met behulp van 
een proportional odds model en de BIS schaal met behulp van een Emax model. De mate van 
ziekte bleek een belangrijke covariaat te zijn voor de diepte van sedatie op zowel de Ramsay 
als BIS schaal, waarbij ziekere patiënten minder propofol nodig hebben. Uit de modellen 
blijkt dat veranderingen in mate van ziekte continue titratie vereist, waarbij bijbehorende 
dosisadviezen worden gegeven. In hoofdstuk 7 is in een pilot onderzoek de invloed van de 
cardiac output en de leverdoorbloeding bestudeerd op de farmacokinetiek van propofol. De 
leverdoorbloeding, gemeten met behulp van de sorbitol concentratie bleek een significante
covariaat voor de klaring van propofol (CL = 1.35 + 1.19 · (LBF-1.32) L/min). De cardiac 
output (gemeten met de Swan-Ganz) was niet van invloed op de PK. Deze bevindingen sug-
gereren dat de leverdoorbloeding een betere voorspeller zou zijn van de PK van propofol dan 
de cardiac output, en mogelijk ook voor andere geneesmiddelen met een hoge extractie ratio. 
In het hoofdstuk perspectives is de voorspellende waarde van gepubliceerde ontwikkelde 
modellen onderzocht in de groep van neonaten. Een leeftijdsgroep waar weinig informatie 
over bekend is en die uitermate kwetsbaar is. De modellen voorspelden systematisch te lage 
spiegels in neonaten onder de leeftijd van 11 dagen, waardoor oversedatie een risico vormt 
en vervolgonderzoek nodig is bij deze groep.
Conclusie
In dit proefschrift werden doseringen geïndividualiseerd van propofol en midazolam voor 
kinderen en kritisch zieke patienten op basis van PK-PD modeling door variabiliteit te 
verklaren met de covariaten lichaamsgewicht, mate van ziekte, hartfalen en leverdoorbloeding 





Dit proefschrift is tot stand gekomen door de fijne samenwerking met heel veel personen
in het St. Antonius Ziekenhuis te Nieuwegein, het Leiden/Amsterdam Center for Drug 
Research te Leiden en het Erasmus MC-Sophia te Rotterdam.
De patiënten, ouders en directe familieleden ben ik zeer erkentelijk voor de deelname aan 
het onderzoek en het in ons gestelde vertrouwen.
Van de afdeling Klinische Farmacie van het St. Antonius Ziekenhuis in Nieuwegein wil ik 
in het bijzonder mijn collega ziekenhuisapotheker Catherijne Knibbe noemen, voor haar 
enorm stimulerende, enthousiaste (zelfs vetbollen tellen leek een prachtig onderzoek) en 
praktische bijdragen. Het was bijzonder de Propofol 6% onderzoekslijn, die indertijd door 
Jan-Gerard Maring en Victorine Koster is geïnitieerd, te mogen voortzetten.
Mathieu Tjoeng ben ik zeer erkentelijk voor de mogelijkheden die hij heeft geboden om  het 
promotieonderzoek uit te voeren.
Mijn collega ziekenhuisapothekers Vera Deneer, Arie van Dijk, Kathleen Simons en Ed 
Wiltink, hebben zich flexibel opgesteld tijdens mijn opleiding tot ziekenhuisapotheker en
mij de ruimte gegeven om te promoveren.
De collega’s in opleiding en deels kamergenoten hebben gezorgd voor de nodige gezel-
ligheid en stimulans: Robert ten Broeke, Jeroen Diepstraten, Ewoudt van de Garde (met 
wie ik op bijzondere wijze de laatste fase samen heb doorlopen), Tjetske Gerbranda, Ankie 
Harmsze en Gitte Melenhorst-de Jong.
Verder heeft de hele afdeling Klinische Farmacie zijn steentje bijgedragen. Dit betreft in 
het bijzonder het FarmaToxLab waar ik met veel plezier de concentraties van propofol in 
grote aantallen bloedmonsters heb kunnen bepalen; de afdeling productie, die wekelijks de 
propofol 6% spuiten bereidde voor het onderzoek en de afdeling logistiek die het transport 
verzorgde naar Rotterdam.
Ook de oud-collega ziekenhuisapothekers wil ik graag noemen: Loraine Lie-A-Huen, Paul 
Kuks, mijn tijdelijke opleider en Rogier Lange die mij als projectapotheker enthousiast 
maakte voor de Propofol 6% onderzoekslijn.
Kobra Waizy heeft in het kader van haar bijvak belangrijke bijdragen geleverd aan het 
volwassen ICU onderzoek en heeft gezorgd voor een nieuwe impuls aan deze studie.
De afdeling Intensive Care van het St. Antonius Ziekenhuis ben ik zeer erkentelijk voor 
de goede samenwerking, de ondersteuning van het onderzoek en de zeer fijne sfeer. In het
bijzonder wil ik hierbij alle anesthesiologen en assistenten in opleiding (m.n. Ferenc Boom 
en Jurgen de Graaff) vermelden voor hun bijgedragen aan de patiëntenselectie, de uitvoering 
van het protocol en de klinische uitleg.
De ICU verpleegkundigen hebben een grote rol gespeeld bij het afnemen van de talloze 
bloedmonsters, het scoren van de diepte van de sedatie en het creëren van een goede sfeer. 
De leden van de Sedatiewerkgroep: Leon Aarts, Leo Bras, Annette de Bruijn, Roelie Deuten, 
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Enny Noordzij en Aletta van der Veen hebben belangrijke bijdragen geleverd aan de ontwik-
keling en de implementatie van het onderzoeksprotocol.
Leon Aarts ben ik in het bijzonder erkentelijk voor het opstarten indertijd van de ICU studie 
in Nieuwegein en voor het leggen van de contacten in Rotterdam. Ik vind het bijzonder 
plezierig dat er inmiddels een vervolgstudie loopt in samenwerking met de afdeling Neuro-
logie en het Laboratorium van de Apotheek van het UMCG te Groningen.
Het Klinisch Chemisch Laboratorium van het St. Antonius Ziekenhuis heeft de logistiek van 
de propofol buizen verzorgd en de serum concentraties van de triglycerides bepaald.
Ellen Tromp heeft hulp geboden op gebied van de statistische analyse van de onderzoeksge-
gevens met het programma SPSS.
Uit het LACDR en LAP&P Consultants wil ik in het bijzonder de belangrijke bijdragen van 
Joost deJongh aan de ontwikkeling van de geïntegreerde farmacokinetisch-farmacodyna-
mische (PK-PD) modellen noemen. Beste Joost, je gaf de burger weer moed als we er niet 
uitkwamen en het beste model een rechte lijn bleek te zijn. Ik heb de uitstapjes naar Leiden 
altijd erg gewaardeerd. We kwamen altijd weer met goede ideeën en vol enthousiasme terug 
in Nieuwegein. Ik hoop dat we contact blijven houden.
Uit het Erasmus MC-Sophia wil ik graag de bijdragen van Sandra Prins noemen, indertijd 
arts-onderzoeker, die van doorslaggevende betekenis zijn geweest voor het verkrijgen van 
de gegevens van de studie in kinderen. Dankzij je nachtelijke inspanningen en het vertrou-
wen dat ouders in je hadden is deze studie vlot verlopen.
De afdeling Intensive Care Chirurgie ben ik erkentelijk voor de bijdrage en hulp aan het 
onderzoek bij de kindjes.
Ook de input van Monique van Dijk was essentieel bij de ontwikkeling van de modellen.
Verder wordt de bijdrage en hulp van de Apotheek in Rotterdam erg op prijs gesteld. Met 
name Ron Mathôt wil ik noemen voor zijn ideeën op het gebied van PK-PD en voor de 
analyse van midazolam en metabolieten. 
Ron van Schaik ben ik erkentelijk voor de DNA analyses en zijn input hieromtrent.
Karel Allegaert ben ik erkentelijk voor het beschikbaar stellen van de propofol spiegels van 
de neonaten voor het laatste hoofdstuk.
Paula Berkemeyer heeft gezorgd voor de lay-out van het boekje. Haar creativiteit en puntjes 
op de i heb ik zeer gewaardeerd.
Verder zou ik graag nog mijn schoonouders willen noemen, die met veel liefde Jasmijn 
menig keer hebben opgevangen.
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Lieve Wendy en Kim,
de laatste in de rij van de zussen. Wen, ik realiseer mij nu pas wat promoveren inhoudt. Ik 
heb jou eigenlijk nooit horen klagen. Je adviezen heb ik zeer op prijs gesteld! Kim, de jaren 
van onderzoek heb ik met jou mogen delen. Heerlijk om even bij je langs te kunnen lopen 
(zal ik straks wel missen) en alle onderzoeksperikelen op de tennisbaan te delen. Ik heb je in 
de laatste fase wel gemist, hoor!
Martijn, je hulp heb ik erg gewaardeerd. Heel veel succes met jouw afronding.
Lieve papa en mama, jullie bewegen hemel en aarde voor ons. De laatste maanden heb ik 
weer als vanouds achter mijn bureautje boven gezeten, terwijl jullie voor Jasmijn zorgden. 
Ik moet zeggen, het was wel heerlijk om weer kind te zijn. Fijn te zien dat Jasmijn ook zo 
intens geniet. Mama, je bezoek aan de dierentuin om ideeën op te doen voor de stellingen 
zal ik niet snel vergeten.
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Stellingen behorend bij het proefschrift
Don’t be afraid! Population PK-PD modeling as the basis for individualized 
dosing in children and critically ill
1. Populatie PK-PD modellering is een krachtige methode om te komen tot 
geïndividualiseerde doseeradviezen bij kinderen.
 Dit proefschrift
2. Kinderen hebben hogere propofol doses nodig als gevolg van verschillen in 
farmacokinetiek en niet in farmacodynamiek.
 Dit proefschrift
3. Propofol heeft in kinderen een beter voorspelbaar effect dan midazolam.
 Dit proefschrift
4. De mate van kritisch ziek-zijn is een belangrijke determinant voor de diepte 
van sedatie, waarbij ziekere patiënten minder propofol nodig hebben.
 Dit proefschrift
5. Bij pasgeborenen is allometrische schaling van de klaring op basis van 
lichaamsgewicht en de factor ¾ niet toepasbaar.
 Dit proefschrift
6. Werken volgens protocol levert verrassende werkwijzen op.
7. Betrokkenheid bij de verzameling van de data is een essentieel onderdeel van 
populatie PK-PD modellering.
8. Alle dingen zijn giftig en er is niets dat geen gif bevat; alleen de dosis zorgt 
ervoor dat iets niet giftig is.
 Paracelsus 1493-1541
9. De ziekenhuisapotheker heeft een belangrijke rol bij het aanpassen van de 
geneesmiddeldosering aan individuele patiënt karakteristieken.
10. Wij zingen vaak slaapliedjes voor onze kinderen opdat wijzelf zouden kunnen 
slapen.
 Kahlil Gibran 1883-1931
11. De beste tijd om op vakantie te gaan is wanneer je er geen tijd voor hebt.
Rifka Peeters                                                                     Leiden, 28 november 2007

